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1 INTRODUCTION 
The importance of pigs in translational biomedical research has been on a constant 
increase, as their anatomical and physiological suitability as model animals is distinct 
(Aigner et al. 2010). Furthermore, pigs are considered a feasible source of 
replacement organs or tissues in the context of xenotransplantation (Petersen et al. 
2009). But potential donor animals need to be tailored in their genetic properties as an 
imperative prerequisite for overcoming detrimental graft rejection processes (Sachs 
and Galli 2009). Somatic cell nuclear transfer has evolved into the preferential 
transgenic technology for achieving this (Melo et al. 2007). However, even though it 
is a successful method for generating novel transgenic pig lines, efficiency in large 
scale reproduction of already established lines has been disappointingly low (Palmieri 
et al. 2008). A feasible rectification of this issue can be found in the establishment of 
breeding herds where transgenic pigs are expanded by means of natural reproduction. 
By this, substantial numbers of experimental animals can be generated within a viable 
time frame. The conflicting matters of inbreeding and segregation of multiple 
transgenes, however, have to be taken into account. Rising inbreeding coefficients 
have been connected to lower productivity of breeding stock (Charlesworth and 
Charlesworth 1987; Ralls et al. 1988; Lynch 1989; 1991). While homozygosity of 
transgene integration sites would rectify the problem of transgene segregation and 
limit time requirements, it can only be achieved on the expense of inbreeding. 
Reproduction of already established (multiple) transgenic pigs by breeding can 
therefore be accomplished if the issues of time, transgene segregation and inbreeding 
are weighed against each other and a suitable breeding strategy that accommodates all 
of  them is identified. When incorporating novel transgenes into already established 
breeding herds, selection of transgenic founder animals has to be performed on the 
basis of careful evaluation of genomic and expression analyses in order to be able to 
fully exploit cumulative effects of transgenes in multiple transgenic animals.  
The aim of this work was to identify a suitable breeding strategy for already 
established lines of transgenic pigs for xenotransplantation research and select 
founders from novel transgenic lines for incorporation into the breeding herd. 
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2 REVIEW OF THE LITERATURE 
 
2.1 The pig as a model species in biomedical research 
 
Although the predominant species of animals in biomedical research are still rodents, 
the pig becomes an ever more important model animal for numerous applications 
(Swindle in Conn 2008), especially in the context of ‘translational’ medicine that 
spans the gap between basic research and clinical trials (Wehling 2008). 
Rodent models may have a well defined genetic background and suit research in terms 
of space requirements and subsequent cost effectiveness (Rand 2010), but generally, 
surgery or sample taking as well as instrumentation are more easily accomplished in 
animals larger than a mouse (Roberts et al. 2009). This alone does not necessitate the 
pig as a model species for biomedical research. However, pigs share many more 
anatomical and physiological similarities with humans than mice, rats or other large 
domestic animals do. Consequently, the pig models the human situation in various 
ways more accurately than other species do.  
Pigs are truly omnivorous animals and among all large domestic animals their 
gastrointestinal morphology, digestive effectiveness, as well as their energy 
metabolism (Aigner et al. 2010; Miller and Ullrey 1987; Spurlock and Gabler 2008) 
correspond to that of humans most closely, making swine the suitable candidates for 
research in the fields of digestion, nutrition, or metabolic syndrome. Meyer (1996) 
reported on the similarities in porcine and human epidermal and dermal structures, 
including the unpronounced body hair layer and the size, orientation and distribution 
of blood vessels. Wound healing in pigs has been found to resemble that in humans in 
many ways (Sullivan et al. 2001). Cardiovascular structures in pigs share numerous 
anatomical and physiological characteristics with humans, for example similar sized 
heart and blood vessels (Smith et al. 1990), a right side dominant conduction system 
as can be found in the majority of humans, and no significant collateral circulation in 
the coronary system (Swindle in Conn 2008). For these reasons, the pig is a popular 
model for research on myocardial infarction. Porcine and human lungs feature 
abundant common characteristics. Rogers et al. (2008) reviewed the available 
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information on aspects of porcine airways and lung that relate to Cystic Fibrosis, and 
could show that porcine and human lungs correspond with respect to volume, 
development of lobularity, pleural structure, and vascular supply, amongst other 
aspects. 
In addition to these physiological and morphological analogies, Wernersson et al. 
could demonstrate in 2005 that on the genomic level the pig is also much more similar 
to humans than the mouse is. By generating ≈ 3.84 million shotgun sequences (0.66X 
coverage) from the pig genome, he found that almost all ultra-conserved elements in 
the human genome can also be detected in the pig, putting it in closer evolutionary 
relationship to man than rodents. 
Compared to other large domestic animals, pigs are superior with respect to their 
reproductive performance (Aigner et al. 2010). Relatively early sexual maturity, short 
generation intervals, and large litters in combination with year round breeding 
constitute desirable traits in animal models. 
 
Disease in pig models may be of spontaneous onset, for example artherosclerosis, 
obesity or gastric ulcers (Roberts et al. 2009), or it may be surgically or medicinally 
induced (Swindle in Conn 2008). Alternatively, pigs may be genetically modified for 
the development of new disease models or for applications in the field of 
xenotransplantation. 
 
 
2.2 Established pig models  
2.2.1 Neurodegenerative diseases 
 
Alzheimer’s disease is a neural disorder leading to memory loss, confusion and, 
ultimately, to a breakdown of bodily functions and death. While in most cases 
Alzheimer’s is a multifactorial disease that occurs sporadically, a familial form of 
autosomal dominant inheritance also exists (Kragh et al. 2009). Causative genetic 
predispositions include mutations in the amyloid precursor protein (APP) gene, and in 
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the presenilin 1 (PSEN1) and presenilin 2 (PSEN2) genes. These mutations are 
associated with a change in the production of the Aβ fragment of APP which 
eventually leads to neuron loss following the formation of neuritic plaques (Hardy et 
al. 2002). 
Although mice transgenic for a mutated human APP gene form these neuritic plaques, 
extensive neuron loss does not occur in them (Takeuchi et al. 2000). Therefore, Kragh 
et al. (2009) postulated the generation of an Alzheimer’s disease model in an animal 
that is evolutionarily closer to humans to obtain a more homologous model. They 
chose to produce a transgenic Göttingen miniature pig via so-called handmade cloning 
using a splice variant of human APP with a dominant mutation known to cause 
Alzheimer’s disease. They gained seven healthy piglets that showed a strong 
expression of the transgenic protein in the brain. Neuropathological impairments are 
expected to develop as the pigs become older. 
 
Huntington’s disease affects specific neurons leading to impaired muscle 
coordination, cognitive decline and dementia. It is an autosomal dominant disorder 
ascribed to a mutation in the huntingtin gene (Graveland et al. 1985).  
Mouse models with a targeted modification in their endogenous huntingtin gene that 
mimics the genetic situation in human patients fail to exhibit full Huntington 
phenotypes with widespread neuronal cell death (Wheeler et al. 1999). In an attempt 
to generate an alternative animal model, Matsuyama et al. (2000) identified and 
characterised the Huntington’s disease gene homologue in miniature pigs and found 
that the disease-relevant segments of the gene and the protein expression profile were 
more similar to the human version than that of rodents. Five transgenic founder piglets 
derived from DNA microinjection into Göttingen miniature pig embryos and each 
with one to three integration sites of a mutated porcine huntingtin gene were generated 
by Uchida et al. (2001). Information about expression profiles or developing 
phenotypes has not been made available so far. 
 
Retinitis pigmentosa is a group of heritable progressive retinal disorders leading to 
vision impairments and ultimately to blindness. A large number of different genes 
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have been associated with the development of retinitis pigmentosa, including 
mutations in the gene for rhodopsin, the visual pigment on the rod photoreceptors 
(Petters et al. 1997).  
Various rodent models of retinal dystrophies are already available. However, 
differences in the number and distribution of photoreceptors, as well as in overall eye 
size, between the human and the rodent eye enforce limits on the usefulness of these 
models (Gregory-Evans and Weleber 1997). With respect to these particulars the 
porcine eye shares more similarities with the human eye suggesting that a pig eye 
model with a specific genetic flaw would react in a similar way as humans do 
(Gregory-Evans and Weleber 1997). Petters et al. (1997) describe the generation of 
transgenic pigs expressing a porcine rhodopsin with a mutation known to cause severe 
rod photoreceptor degeneration in man. One founder animal was established by DNA 
microinjection of the expression vector, and transmission and segregation of the 
transgenes over two generations led to two independent mutant pig lines. These pigs 
develop a form of retinal degeneration which closely corresponds to that of humans 
with the same mutation in the rhodopsin gene. 
 
2.2.2 Cardiovascular diseases 
 
Pig models in cardiovascular research are based largely on the many shared 
anatomical and physiological characteristics between pigs and humans. Most of these 
models make use of swine as experimental settings for invasive procedures, 
development of medical devices or for surgical or dietary induction of specific 
pathological conditions such as myocardial infarction or artherosclerosis (Swindle in 
Conn 2008).  
However, the establishment of a transgenic pig over-expressing the endothelial cell 
nitric oxide synthase (eNOS) (Hao et al. 2006) provides a swine model on the basis of 
genetic modification for a better understanding of cardiovascular regulation. eNOS-
derived nitric oxide is said to serve a wide array of important functions in the 
cardiovascular system. Vascular tone, vascular smooth muscle cell proliferation or 
thrombosis is all influenced by nitric oxide (Huang 2009). Endothelial dysfunction 
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involving a decrease in nitric oxide availability is a common feature of many 
cardiovascular risk factors, as has been confirmed by the phenotypes of numerous 
transgenic or knock-out rodent models (Huang et al. 1995; Moroi et al. 1998; 
Freedman et al. 1999). But several differences in the cardiovascular system of rodents 
and humans have made direct extrapolation of data to humans more feasible from a 
pig rather than a rodent model.  
Hao et al. (2006) used additive gene transfer and subsequent somatic cell nuclear 
transfer to produce four Yucatan miniature pigs transgenic for a recombinant porcine 
eNOS protein. Expression of the transgenic eNOS on the vascular endothelium and 
distinction from the endogenous protein could be demonstrated. These pigs are to be 
used as models in long term studies further clarifying the role of eNOS in the 
cardiorespiratory system. 
 
2.2.3 Diabetes mellitus 
 
The term diabetes mellitus stands for a number of metabolic disorders with 
multifactorial genetic, immunological and lifestyle aetiology. They all share the 
common characteristic of elevated blood glucose levels due to insufficient availability 
of insulin in the sufferer. A distinction has to be made between type 1 diabetes, where 
the main causative matter is an inability of the pancreatic beta-cells to produce 
sufficient amounts of insulin (Tuomi 2005), and type 2 diabetes which results from a 
peripheral insulin resistance (Martin et al. 1992) leading to progressive pancreatic 
beta-cell dysfunction (Prentki et al. 2006). Other types of diabetes with various causes 
are less common. 
In the past, numerous swine models with a diabetic pathogenesis that show symptoms 
of altered glucose tolerance and insulin resistance, or elevated blood glucose and 
insulin levels, had been established by selective breeding of certain strains of Yucatan 
(Phillips et al. 1982), Chinese Guizhou (Xi et al. 2004) and Göttingen (Johansen et al. 
2001; Larsen et al. 2004) miniature pigs. Other diabetic swine models utilising 
Sinclair (Dixon et al. 1999) and Göttingen (Larsen et al. 2003) miniature pigs, 
developed the disease following induction by Streptozotocin or Alloxan 
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administration (Yamamoto et al. 1981).  
Umeyama et al. (2009) established the first genetically modified pigs exhibiting the 
pathophysiological characteristics of diabetes. These pigs carry a dominant-negative 
mutation of the hepatocyte nuclear factor 1 alpha (HNF1A), causing the so-called type 
3 of maturity-onset diabetes in the young (MODY3). Previously, this correlation had 
already been demonstrated in a comparable mouse model (Watanabe et al. 2007). A 
combined method of intracytoplasmic sperm injection-mediated gene transfer and 
somatic cell nuclear transfer was used to generate four viable transgenic animals that 
showed persistently elevated non-fasting blood glucose levels and abnormal oral 
glucose tolerance tests. 
Recently, a transgenic pig model expressing a dominant-negative glucose-dependent 
insulinotropic polypeptide receptor (GIPRdn) (Renner et al. 2010) has been generated 
and is expected to shed light on a feature in the clinical picture of type 2 diabetes that 
can be universally found in human patients: an impaired incretin function (Meier et al. 
2001). The two incretin hormones glucose-dependent insulinotropic polypeptide (GIP) 
and glucagon-like peptide-1 (GLP-1) enhance glucose-induced insulin secretion in 
response to the presence of nutrients (Baggio and Drucker 2007). Earlier experiments 
of Herbach et al. (2005) indicated that over-expression of a dominant-negative GIP-
receptor in mice leads to a severe diabetic phenotype with early-onset diabetes and a 
pronounced reduction and structural alteration in pancreatic islets. However, these 
findings contrast the effects of a lack of functional GIP receptor expression described 
for other mouse models (Miyawaki et al. 1999). Renner et al. (2010) generated GIPRdn 
pigs in order to clarify the role of GIP receptor signalling in the pathogenesis of 
impaired pancreatic islet function. Lentiviral vectors were used to generate transgenic 
pigs that mimic important aspects of human type 2 diabetes mellitus. These pigs 
initially display a reduced GIP action with impaired oral and, subsequently, also 
impaired intravenous glucose tolerance tests, and progress to a reduction in pancreatic 
beta-cell proliferation and overall beta-cell mass. 
Additionally, Aigner et al. (2010) report on the ongoing establishment of a pig model 
with disturbed intravenous glucose tolerance and reduced insulin secretion due to a 
point mutation in the insulin (INS) gene. The corresponding mutation in the mouse 
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insulin2 (Ins2) causes a progressive diabetes mellitus with a pronounced reduction in 
total pancreatic islet and beta-cell volume (Herbach et al. 2007). Comprehensive data 
on the characterisation of this novel pig has not been made available yet. 
 
2.2.4 Cystic Fibrosis 
 
The pathology of cystic fibrosis involves multiple organs, including the pancreas, 
intestine, liver, vas deferens and, most commonly, the lung. Persistent airway 
inflammation and chronic bacterial infections leading to progressive lung destruction 
and pancreatic disease cause most of the morbidity and mortality in cystic fibrosis 
patients (Elston et al. 2007; Rogers et al. 2008a).  
Cystic fibrosis is a disease of autosomal recessive inheritance of mutations in the gene 
encoding the cystic fibrosis transmembrane conductance regulator (Cftr) (Rogers et al. 
2008; Meyerholz et al. 2010). More than 1000 different mutations in the Cftr gene are 
associated with the manifestation of cystic fibrosis (Welsh et al. 2009). The deletion 
of phenylalanine at position 508 (∆F508) in the Cftr gene is the most common one 
(Davis et al. 1996), accounting for approximately 70% of cystic fibrosis alleles 
(Zielenski et al. 1995). The ∆F508 mutation causes different defects on human Cftr. In 
Cftr/∆F508 patients, most of the mutant protein is retained within the endoplasmic 
reticulum and its maturation to the plasma membrane is prevented (Dorwart et al. 
2004). In addition, chloride channel activity of the remaining processed Cftr is 
reduced, and the protein’s stability on the cell surface is impaired (Swiatecka-Urban et 
al. 2005). The combination of these deficiencies results in the pathological 
manifestation of cystic fibrosis. However, the exact mechanisms underlying these 
processes and the extent to which each of the defects is responsible for the 
development of cystic fibrosis pathology, is as of now still largely unclear (Meyerholz 
et al. 2010a).  
A number of genetically engineered mouse models with the ∆F508 mutation in their 
Cftr gene, displaying varying phenotypes from almost absent to near 100% mortality 
rate before maturity, have been characterised since the early 1990s (Guilbault et al. 
2007). None of these mouse models develop the chronic lung inflammations that are 
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characteristic for the human cystic fibrosis pathology. Neither do any of them exhibit 
evidence of pancreatic disease (Colledge et al. 1995; Zeiher et al. 1995). Ostedgaard et 
al. (2007) postulate that the severity of the Cftr/∆F508 processing defect is much more 
pronounced in humans than in mice, accounting for the obvious compensation 
mechanisms in some mutant mouse lines that prevent marked phenotypes. Their data 
also suggests that in pigs the effect of a ∆F508 mutation on the posttranslational Cftr 
processing is less than in humans but still a lot more profound than in mice. 
The pig lung has already served as an excellent model for the normal and diseased 
human lung, or the effect of therapeutics, in many ways (Rogers et al. 2008). 
Structural and size similarities between porcine and human lungs (Jones et al. 1975) 
facilitate extrapolation of porcine data to the human situation. In the context of cystic 
fibrosis, particulars of electrolyte transport by airway epithelia are a critical point. In 
vitro experiments demonstrated quantitative similarities in epithelial ion transport 
between pig and man (Liu et al. 2007). However, even though defects in electrolyte 
transport due to a limited availability and reduced activity of the Cftr channels are 
seen as a hallmark of cystic fibrosis (Quinton 2007), knowledge about electrolyte 
transport in the human cystic fibrosis lung, especially during the neonatal period 
before onset of associated lung symptoms, is extremely limited (Rogers et al. 2008). 
Other parameters, such as mucociliary clearance defects, also call for detection before 
the development of severe lung disease. This, too, has been difficult to achieve in 
humans. On that account, the pig might become a useful tool in clarifying the 
(patho)mechanisms of the abnormal processes in cystic fibrosis affected lungs, and 
align the onset of symptoms to biochemical or morphological changes in the airways.  
Rogers et al. (2008b) chose this species to establish two new animal models of cystic 
fibrosis because the pig has become increasingly popular in biomedical research, and 
its similarities with man in terms of anatomical, histological, biochemical, and 
physiological features are distinct.  
Pigs with Cftr-null alleles were generated to lack any Cftr function, so a full porcine 
cystic fibrosis phenotype could be observed. Adeno-associated virus-mediated gene 
targeting and subsequent somatic cell nuclear transfer were employed to insert the 
targeting vector into the Cftr gene via homologous recombination. Nine male 
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heterozygous Cftr-null piglets were gained, which sired numerous heterozygous male 
and female offspring. By mating male and female heterozygous animals to each other, 
Rogers et al. (2008a) established homozygous Cftr-null pigs. Loss of CFTR chloride 
channel activity could be detected in newborn piglets, as well as the development of 
meconium ileus, exocrine pancreatic insufficiency, focal biliary cirrhosis and gall 
bladder abnormalities. This phenotype mimics that of human newborns with cystic 
fibrosis, however the symptoms appear to be accelerated and more severe in these 
particular pigs (Meyerholz et al. 2010a). Lung affection could also be demonstrated in 
homozygous Cftr-null piglets. Evidence for defects in eradicating bacteria from the 
lung was found shortly after birth. Over time, the pigs developed spontaneous lung 
disease that was largely similar to that observed in human patients, such as 
spontaneous inflammation, airway remodelling, mucus accumulation and chronic 
bacterial infection (Stoltz et al. 2010). 
Additionally, Rogers et al. (2008b) attempted the establishment of a pig carrying the 
∆F508 mutation in its Cftr gene. The techniques applied in the generation of these 
pigs were the same as were used for the Cftr-null model, and produced four transgenic 
animals. This model might offer a progression towards understanding the mechanisms 
of Cftr metabolism. However, so far a phenotypic evaluation of these pigs has not 
been made available. 
 
 
2.3 Pigs as donor animals in the context of xenotransplantation 
 
In xenotransplantation lies a great potential for providing life-saving treatment for 
patients with many end-stage diseases leading to organ failure. The gap between 
demand and availability of appropriate allogeneic organs for transplantation to treat 
these patients is ever increasing as life expectancy rises (Petersen et al. 2009). As a 
result, non-human sources of replacement organs and tissues have to be explored and 
exploited (Ekser et al. 2009).  
Pigs are considered a feasible source because of their physiological and organ size 
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similarities to humans, in addition to their growth capacity and favourable breeding 
characteristics (Petersen et al. 2009; Sachs and Galli 2009). To date, the biggest hurdle 
in utilising pigs as donor animals for organs or tissue remains in the immunological 
barriers between the porcine and human organism (d’Apice and Cowan 2009; 
Sprangers et al. 2008; Yang and Sykes 2007).  Immunological rejection of the 
xenograft that cannot be controlled by immunosuppressant regimens is the result. 
Various strategies for genetically altering pigs in order to overcome these 
immunological incompatibilities (Sachs and Galli 2009) have already been, or are 
currently being, pursued. Building on the availability of a number of different 
techniques for modification of the porcine genome that can be applied without posing 
major ethical problems (Sprangers et al. 2008), significant progress in graft survival in 
pig to non-human primate transplantation settings has already been achieved (Petersen 
et al. 2009). The mechanisms leading to xenograft rejection include several different 
immunological processes that have to be addressed by tailored modification of the 
donor pig in order to be successful in prolonging graft survival. 
 
2.3.1 Hyperacute xenograft rejection  
 
Hyperacute rejection occurs within seconds to minutes or hours of transplantation 
(Rand 2010) and is characterised by an almost immediate loss of graft function and 
distinct changes in the physical appearance of the graft (Petersen et al. 2009). It is 
mediated primarily by natural antibodies that are directed against carbohydrate 
epitopes synthesised by the enzyme α1,3-galactosyl-transferase (Gal) (Klymiuk et al. 
2010). Most species, including pigs, express this enzyme. However, humans, apes and 
Old World Monkeys do not. Moreover, they possess natural preformed antibodies that 
are able to bind these Gal epitopes on porcine vascular endothelium, leading to an 
activation of the complement system and coagulation cascade, and the subsequent 
destruction of the xenograft (Yang and Sykes 2007).  
By generating pigs lacking a functional Gal expression, the antigens become absent 
from the donor organs and cannot trigger a reaction by the recipient. Various 
approaches in targeting the gene for Gal in pigs have been described (Dai et al. 2002; 
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Lai et al. 2002; Harrison et al. 2004; Ramsoondar 2003; Sharma et al. 2003) . Phelps 
et al. (2003) reported on the establishment of the first Gal knock out (GalKO) pigs 
completely deficient of a functional version of the enzyme. These pigs were generated 
by two rounds of homologous recombination with a knockout targeting vector and 
subsequent somatic cell nuclear transfer. Expression analysis including an in-vivo 
immunogenicity test in GalKO mice demonstrated the absence of Gal epitopes on the 
porcine cells. Other transgenic pigs lacking functional Gal expression through loss of 
heterozygosity mutations have been established since (Kolber-Simonds et al. 2004). 
A range of different organs derived from GalKO pigs, from kidneys (Yamada et al. 
2005) and lungs (Schroeder et al. 2005) to hearts (Kuwaki et al. 2005; Hisashi et al. 
2008; Shimizu et al. 2008), have already been put to test in various xenogenic 
transplantation and perfusion settings, demonstrating the prolongation of graft survival 
in the absence of Gal epitopes, and the lowered requirements for immunosuppression 
(Tseng et al. 2005).  
Lowering the incidence of Gal epitopes in porcine tissues by expressing enzymes that 
utilise the same substrate as Gal and therefore compete with it (Koike et al. 1997; 
Sharma et al. 1996; Costa et al. 1999; Miyagawa et al. 2001), constitute an alternative 
approach to combating the effect preformed xenoreactive antibodies have on the 
donor organ or tissue. However, since even smallest amounts of Gal epitopes trigger 
immunological reactions in the graft recipients, this method seems insufficient in 
preventing hyperacute rejection (Yang and Sykes 2007). 
The expression of one or more human complement regulators on porcine tissue is a 
critical component in creating the optimal donor pig (d’Apice and Cowan 2009). The 
cross-species incompatibilities in controlling complement activation mean that porcine 
complement regulators are not efficient in directing human complement activation and 
vice versa (Miyagawa et al 1988). The expression of human decay accelerating factor 
(hDAF), CD59 and/or CD46 on porcine cells have been the most favoured strategies 
for overcoming this problem.  
Expressing hDAF on porcine tissues has been shown to suppress endothelial 
activation and reduce thrombin generation in transplants (Miwa et al. 2010). Different 
attempts at generating pig lines transgenic for hDAF have been made by a number of 
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groups (Cozzi et al. 1994; Langford et al. 1994; McCurry et al. 1995; Lavitrano et al. 
2002), each being successful at expressing the protein endothelial cell specifically. 
Transgenesis for the complement membrane attack complex inhibitor CD59 has been 
used by others in order to protect pig organs from recipient complement (Fodor et al. 
1994; McCurry et al. 1995; Diamond et al. 1996). 
CD46 is an inhibitory complement receptor which, in the physiological situation, 
prevents cells from damage through autologous complement (Liszewski et al. 1996). 
Diamond et al. (2001) describe the establishment of a transgenic pig line expressing 
high levels of human CD46 in a pattern similar to the endogenous situation in man. In-
vivo experiments indicated the effectiveness of this approach in overcoming 
hyperacute rejection. Comparable results were achieved by Zhou et al. (2002), who 
subsequently used these pigs to generate a double transgenic line with hDAF. Kidney 
transplantation experiments into baboons using organs of CD46 transgenic pigs 
established by Loveland et al. (2004) provided further evidence for the effective 
protection of transgenic tissues against antibody and complement-mediated lysis or 
damage. 
In addition, a variety of multiple transgenic pigs expressing two or three genes of the 
above have been generated by Byrne et al. (1997), Chen et al. (1999) or Cowan et al. 
(2000), among others. 
 
2.3.2 Acute humoral xenograft rejection 
 
If hyperacute rejection is prevented, acute humoral rejection develops (Schuurman et 
al. 2003), likely induced by low levels of natural and elicited xenoreactive antibodies 
(Yang and Sykes 2007). The exact mechanisms that trigger the ensuing complement 
activation and thrombotic microangiopathy are not known yet, however, results of 
Shimizu et al. (2006) indicate that incomplete cross-species regulation of complement 
activation might contribute to the process. Cowan and d’Apice (2008) point out that 
the ultimate killer of most xenografts has proven to be thrombosis. Immune mediated 
endothelial injury converts the normally anticoagulant endothelial surface to a 
procoagulant state (Bach et al. 1994). This is regarded as the most important aspect in 
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the development of microvascular thrombosis occurring during xenograft rejection. A 
number of factors modulating platelet activation and the coagulation cascade have 
been under discussion for being able to prevent the destruction of the xenograft by 
coagulopathies.  
CD39 is responsible for the inhibition of ADP-induced platelet aggregation. Studies 
have shown that transgenic expression of CD39 is able to protect transplants from 
thrombosis (Dwyer et al. 2004).  
Tissue factor pathway inhibitor (TFPI) targets tissue factor, which is the initiator of 
the extrinsic activation of the coagulation cascade. Contrary to earlier findings of 
Kopp et al. (1997), Lee et al. (2008) could show that porcine TFPI exercises similar 
anticoagulant activity in human coagulation as does human TFPI. Since studies were 
performed in-vitro, however, the in-vivo effect still remains to be elucidated.  
Human thrombomodulin (hTM) is a membrane protein on endothelial cells. It is an 
important factor in the generation of the anticoagulant activated protein C (aPC). By 
forming a thrombin/thrombomodulin complex, it enhances the activation level of 
protein C 20-fold (Taylor et al. 2001). As had been suggested in in-vitro studies, 
porcine thrombomodulin is unable to efficiently bind human thrombin (Siegel et al. 
1997; Kopp et al. 1998), resulting in an inadequate activation of human protein C and 
subsequently in increased coagulation. Roussel et al. (2008) could show that even 
though porcine thrombomodulin binds to human thrombin and reduces the 
procoagulant characteristics of thrombin significantly, its cofactor activity in the 
thrombin/thrombomodulin complex for protein C activation is only ~10% that of 
human thrombomodulin. Incorporating hTM in xenogeneic transplant tissues by 
expressing it on endothelia might therefore offer benefits in terms of coagulation 
cascade inhibition. As Petersen et al. (2009) report, fibroblasts isolated from hTM 
transgenic pigs showed an elevated production of activated protein C in an in-vitro 
coactivity assay. So far, possible in-vivo effects have not been published yet. 
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2.3.3 Cell-mediated xenograft rejection 
 
In allotransplantation, cellular rejection mechanisms are the major issues that have to 
be dealt with. This chronic rejection process occurs between days and weeks after 
transplantation and is mainly mediated by T- lymphocytes and macrophages (Petersen 
et al. 2008). It can be combated by detailed immunosuppressive protocols. However, 
incompatibilities between human and porcine cell interactions may limit the 
effectiveness of these protocols in cross-species transplantation (Petersen et al. 2009). 
Transgenic strategies to overcome this cell-mediated rejection of xenografts build on 
the expression of T-cell modulating genes in donor pigs.  
Different approaches including the selective inhibition of CD4+-T-cell activation by 
proteins such as CTLA4-Ig or LEA29Y (Mirenda et al. 2005; Huurman et al. 2007; 
Phelps et al. 2009) have been employed in achieving this. Martin et al. (2005) 
established transgenic pigs that express CTLA4-Ig brain-specifically to be used as 
neuron donors for potential treatment of neurodegenerative disorders.  
A different attempt used human tumor necrosis factor-alpha-related apoptosis-
inducing ligand (TRAIL), which acts as an apoptosis inducing agent (Ursini-Siegel et 
al. 2002) and cell cycle inhibitor on human lymphocytes (Song et al. 2000). As Klose 
et al. (2005) demonstrated, lymphocytes derived from human TRAIL transgenic pigs 
are able to induce apoptosis in a line of immortalised T-lymphocytes in-vitro. 
Neutralising TRAIL with antibodies indicated the TRAIL-specificity of the effect.  
Natural killer (NK) cells play a diverse role in cellular rejection processes in 
xenotransplantation settings. Apart from activating the porcine endothelium upon 
direct contact (Goodman et al. 1996), they have also been shown to infiltrate graft 
tissue (Khalfoun et al. 2000) and exercise direct and antibody-mediated cytotoxicity 
upon porcine cells (Rieben and Seebach 2005). The xenogeneic cytotoxic effect of 
human NK cells can be diminished by expression of the human major 
histocompatibility complex class I molecule human leukocyte antigen (HLA)-E on 
endothelial cells of pig organs, as demonstrated in-vitro by a number of authors 
(Matsunami et al. 2002; Rieben and Seebach 2005; Lilienfeld et al. 2007). HLA-E 
binds specifically to the inhibitory receptor CD94/NKG2A on activated human NK 
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cells and thereby prevents reactivity (Forte et al. 2005). To make use of this effect, 
Weiss et al. (2009) generated transgenic pigs by pronuclear microinjection of genomic 
fragments of HLA-E and human β2-microglobulin into zygotes. These animals 
showed a strong, consistent expression of HLA-E in endothelia of multiple organs. In-
vitro NK cell cytotoxicity assays revealed that the capacity of NK cells to lyse HLA-E 
expressing target cells was markedly reduced, making a contribution of this transgene 
towards ameliorating xenograft survival likely. 
Organs or tissue derived from transgenic pigs appear to be the most imminent option 
in the pursuit of utilising xenotransplantation in order to ameliorate transplant supply 
for our aging population. As many research groups and authors have demonstrated in 
the past years, this designated target seems to be drawing closer.  
 
 
2.4 (Re)producing transgenic pigs 
 
Genetic modification of pigs has been utilised for more than 25 years to refine and 
tailor large animal models for applications in translational biomedicine and 
xenotransplantation. A number of different techniques for additive gene transfer or 
targeted alterations of the porcine genome are available.  
First successful attempts in producing transgenic large animals were made with 
pronuclear DNA microinjection (Brem et al. 1985; Hammer et al. 1985) whereby the 
gene of interest is directly injected into one of the pronuclei of a zygote. This 
technique, however, harbours some problems. Apart from the general inefficiency in 
producing viable embryos with this method (Nottle et al. 2001; Hofmann et al. 2003), 
the unpredictability of the integration site of the transgene leads to great variations in 
expression levels (Clark et al. 1994) or even mosaicism in the resulting embryos 
(Keefer 2004). 
Gene transfer employing the infection capacity of lentiviruses allows integration of 
the transgene into very early embryos (Pfeifer 2004). In lentiviral transgenesis the 
viral genome is integrated into the host chromosome, providing a prerequisite for 
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stable transgene expression (Pfeifer and Hofmann 2009; Pfeifer et al. 2010). 
Efficiency of this method has proven higher than with pronuclear DNA microinjection 
(Hofmann et al. 2003; Whitelaw et al. 2004), however, stable expression of the 
transgene may be compromised by epigenetic silencing of promoter regions or coding 
sequences through DNA methylation (Hofmann et al. 2006).  
Sperm-mediated gene transfer makes use of the ability of spermatozoa to incorporate 
exogenous DNA and pass it on to the oocyte during fertilisation (Lavitrano et al. 
2006). In pigs this method has shown a comparably high efficiency while at the same 
time being very cost-effective (Lavitrano et al. 2003). Incorporation of multiple 
transgenes at the same time (Webster et al. 2005) is feasible but success of the 
procedure depends greatly on the selection of sperm donors and incubation parameters 
(Lavitrano et al. 2003). 
Presently, the leading technique in generating transgenic livestock is somatic cell 
nuclear transfer, also known as cloning (Melo et al. 2007). Genetically altered cells 
originating from foetal, neonatal or adult donors are transferred into enucleated 
oocytes and the resulting embryos are subsequently transferred to recipient animals. 
Campbell et al. (1996) reported the first live offspring derived from this method in 
sheep. Since then, numerous attempts have been successful in applying this technique 
of generating transgenic animals to a variety of species, including pigs (Betthauser et 
al. 2000; Onishi et al. 2000; Polejaeva et al. 2000; Lagutina et al. 2007; Kurome et al. 
2008). The great advantage of somatic cell nuclear transfer compared to other ways of 
generating transgenic animals is the option of site specific introduction of transgenes 
via homologous recombination (Lai et al. 2002; Rogers et al. 2008). So far, this 
method has been the only one that offers such a possibility. 
Campbell et al. (2005) point out that judging the overall efficiency of cloning in 
producing transgenic offspring is difficult because of the large differences in 
experimental protocols, embryo selection and data presentation applied in the various 
reports. However, the percentage of live offspring derived from transferred embryos is 
generally quoted as below 5% (Palmieri et al. 2008; Aigner et al. 2010) across all 
examined species. A number of reasons have been suggested for this limited 
efficiency in the production of cloned piglets. Cloning procedure and in-vitro 
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manipulations might affect the embryos so embryonic signalling to the recipient 
becomes too weak (King et al. 2002; Petersen et al. 2008). Reduced intrauterine 
transport of the embryos (Schmidt et al. 2010) or breed differences between embryos 
and recipients have also been discussed as contributing factors (Estrada et al. 2008; 
Kurome et al. 2008; Koo et al. 2009). The major focus, however, has been on a 
perceived reduction in epigenetic reprogramming of the embryos attributed to the 
cloning procedure. This has been investigated and discussed extensively by numerous 
groups and authors (Dean et al. 2001; Humpherys et al. 2001; Khosla et al. 2001; 
Young et al. 2001; Jiang et al. 2007; Bonk et al. 2008). They have also linked a 
variety of developmental abnormalities to insufficient epigenetic reprogramming of 
the somatic donor cell (reviewed in Tian et al. 2009). However, cloned pigs that are 
actually born alive and grow to maturity appear to show no difference in reproductive 
characteristics compared to wild-type controls. Gestation length, litter size, birth and 
weaning weights are similar, as reported in a variety of studies (Martin et al. 2004; 
Mir et al. 2005; Williams et al. 2006; Shibata et al. 2006).  
The low numbers of transgenic animals that can be generated through somatic cell 
nuclear transfer or any of the other methods make these procedures valuable tools for 
introducing new transgenes into the porcine genome. However, for routinely 
reproducing such animals, these methods are as of now too inefficient and cost 
intensive. Reproduction of already established transgenic lines by breeding seems a 
feasible alternative. 
Cross-generational stability of transgene expression levels has been shown in 
transgenic cattle and pigs derived from somatic cell nuclear transfer (Bordignon et al. 
2003; Brunetti et al. 2008), leading to the conclusion that continuous generation of 
transgenic animals by breeding might be an affordable and reproducible alternative to 
in-vitro techniques. 
 
2.4.1 Pig breeds and pig breeding 
 
In contrast to mouse models where one century of standardised breeding experience 
already exists and numerous suitable strains have been established and characterised, 
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systematic breeding of experimental herds for large animal models is only in the early 
stages of development. A large proportion of current knowledge about pig breeding 
derives from reproduction of conventionally utilised pig breeds in agriculture. The 
term breed refers to a group of animals of a defined species that has been selected by 
people for their heritable similarity in terms of appearance or productive and 
reproductive characteristics (Porter 1993).  
In Europe, directed breeding of conventional pig lines for pork or lard production 
developed in England during the 18th century, when the increasing industrialisation 
led to urbanisation and an enhanced demand of food supplies that could not be derived 
from self-subsistence. Pigs from a number of different countries were imported to 
England and a crossbreed between Asian and Italian pigs with the existing landraces 
turned out the first modern pig breed, the Leicester pig. Small, Middle and Large 
(=Yorkshire) White followed during the first half of the 19th century. These breeds 
were spread throughout Europe and were used to improve the prevalent landraces 
(Nickels 1997). In Germany, a wide variety of new breeds developed until the mid-
20th century. The late 1950s brought a change in the demographics of pig breeds. Pigs 
that had been bred for lard production were successively eliminated and breeding 
began to centralise on meat production to satisfy the increasing demand during the 
economic miracle (v. Lengerken and Wicke in v. Lengerken et al. 2006). German 
Landrace became the predominant breed by far. Other breeds such as Hampshire, 
Duroc, Angler Saddle Pig or Swabian-Hall were at some point during the 1970s on the 
verge of extinction. However, over the course of the 1980s, a few of these breeds were 
rediscovered (Nickels 1997). Today, the most common commercial pig breeds in 
Germany are German Landrace, German Large White and Pietrain or, comprising the 
majority of animals in conventional pig production, hybrids of these breeds (Horst and 
Gregor in Kräußlich and Brem 1997). Some of the rediscovered breeds such as 
Swabian-Hall, Duroc or Hampshire pigs constitute niche populations in pork 
production on the one hand, and an important component in the conservation of old 
farm animal breeds on the other hand. 
In contrast to pig livestock, miniature pigs have been bred specifically for 
experimental use and, later and to a lesser extent, as pets. Miniature pig is the generic 
 
Review of the literature 
 
 
 
21 
 
term for growth-restricted pig breeds or lines with varying heights. Generally, pigs 
with an adult weight of less than 100 kg are called miniature pigs, even though the 
majority are much smaller, most weighing around 15-45 kg when they reach sexual 
maturity (Fisher 1993). The goal in miniature pig breeding was to create a 
conveniently sized animal for research that would be able to compete with other 
experimental animal species and make use of the anatomical and physiological 
similarities between pigs and humans but without the disadvantages of commercial 
pig breeds. Miniature pigs require less housing space, are easier to handle and are 
more cost-effective in terms of feed and experiments due to lower material 
requirements, compared to larger pigs (Swindle 2007). In 1949 the Hormel Institute of 
the University of Minnesota initiated a project to develop a breed of miniature swine 
specifically for use in biomedical research (Bustad 1966). One of the first miniature 
pigs, the Minnesota miniature pig, arose from this effort. Today, there are over 50 
other breeds of miniature pigs worldwide, but only a few of them are regularly used 
for research. The most commonly utilised breeds include the Göttingen, Sinclair, 
Yucatan, and Hanford miniature pigs (Swindle in Conn 2008).  
The Hanford miniature pig, for example, has served as a model for a number of 
neonatal and paediatric diseases (Glauser 1966; Cohen et al. 1990; 1991). Yucatan and 
Sinclair pigs have been extensively used in diabetes research (Phillips et al 1982; 
Dixon et al. 1999; 2002) and as models of cardiovascular disease (Wissler and 
Vesselinovitch 1968; Gal et al. 1990). Sachs et al. (1976) reported on the 
establishment of a partially inbred herd of miniature swine homozygous for a specific 
swine leukocyte antigen allele. This model has been put to use in various 
transplantation settings, such as skin grafting (Leight et al. 1978), bone marrow 
transmissions (Pennington et al. 1988) and liver transplantations (Flye et al. 1999). By 
sequential brother-sister matings, the co-ancestry, also known as inbreeding, of this 
herd has reached levels greater than 90% (Mezrich et al. 2003; Cho et al. 2007).  
This so-called inbreeding is defined by the probability that the two alleles at an 
autosomal locus of an individual are identical by descent, meaning that the parents of 
an individual must have one or more common ancestor for that individual to be termed 
inbred. Inbreeding is measured by the inbreeding coefficient (Wright 1922). 
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Dickerson et al. (1954) showed that in pigs inbreeding in the mother leads to a 
reduction in litter size of approximately 0.2 piglets per 10% rise in the inbreeding 
coefficient. As Dettmers and Rempel reported in 1968, this correlation became 
apparent during the recurrent mass selection for small size in the establishment of the 
Minnesota miniature pig breed. Although litter size underlies great variation 
depending on the exact breed but also on environmental factors, large, commercial pig 
breeds generally farrow more than 10 live piglets per litter (v. Lengerken and Wicke 
in v. Lengerken et al. 2006). Contrary to this, miniature pigs produce average litters of 
no more than 5-6 piglets (Swindle 2007). Due to the limited population size of 
miniature pig breeds, inbreeding becomes inevitable if specific characteristics of the 
breed are to be conserved. Other reproductive parameters such as the number of 
stillborn piglets per litter, the piglets raised in a litter or the average weight gain until 
weaning have been equally shown to negatively correlate with an increase in the 
inbreeding coefficient (Bradford et al. 1958). These unwanted effects, in addition to 
others, are summarised under the term inbreeding depression. 
 
2.4.2 Inbreeding depression 
 
Various studies have indicated that inbreeding causes a shift in mean phenotypes 
towards a reduction in fitness related characters, either taking shape in the form of 
distinct abnormalities or, in a less overt manner, in lower fertility, survival and growth 
rates of individuals with high inbreeding coefficients (Charlesworth and Charlesworth 
1987; Ralls et al. 1988; Lynch 1989; 1991). This is called inbreeding depression. This 
phenomenon has been studied extensively in a variety of species, both theoretically 
(Charlesworth et al. 1990; Bataillon and Kirkpatrick 2000) and experimentally 
(Bradford et al. 1958; Bereskin et al. 1968; Casellas et al. 2009) because it appears to 
play an important role in the evolution of mating systems and challenge the viability 
of restricted populations (Glemin et al. 2003).  
Inbreeding depression is triggered by increased homozygosity of individuals 
(Charlesworth and Willis 2009). The two rivalling hypotheses of partial dominance 
and overdominance are discussed as explanation for the lower overall fitness of inbred 
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individuals. Deleterious but normally recessive and rare traits phenotypically manifest 
themselves in individuals that are homozygous for these particular alleles. Because the 
likelihood for homozygosity at any given gene locus increases with inbreeding, 
recessive traits are more prevalent in inbred populations (Charlesworth and 
Charlesworth 1999). The inbred line becomes fixed for recessive detrimental alleles, 
leading to an overall reduced fitness of the population (Charlesworth and 
Charlesworth 1987). This explanation of partial dominance as the origin of inbreeding 
depression was first outlined by the maize scientist Davenport (1908). 
In the hypothesis of overdominance, inbreeding depression is ascribed to the 
superiority of heterozygotes over homozygotes at specific gene loci (Charlesworth and 
Charlesworth 1987). Recessive or partially recessive alleles that in homozygosity 
result in a phenotype that decreases fitness can survive in a population because their 
heterozygous occurrence produces an advantage for the affected individual. For 
example, the overdominant sickle-cell allele in humans protects against malaria in 
heterozygotes, providing a distinct advantage in malaria-endemic regions. On the 
other hand, homozygosity for this partially recessive allele causes sickle-cell anaemia 
(Currat et al. 2002), greatly shortening the life expectancy of patients. In an inbred 
population, homozygosity for overdominant alleles increases and disadvantageous 
phenotypes become prevalent.  
The level to which each of these phenomena contribute to inbreeding depression has 
been discussed extensively since these theories were formulated in the early 20th 
century, with shifting emphasis over the decades. In recent years, molecular 
evolutionary studies and fine mapping of genes involved in fitness variation support 
the notion that the main cause for inbreeding depression is to be found in an 
accumulation of recessive deleterious mutations at many gene loci, attributing a major 
part of inbreeding depression to the theory of partial dominance. Charlesworth and 
Willis (2009) argue that the higher fitness of heterozygotes rarely derives from single 
overdominant loci but only appears to do so because mapping of so-called quantitative 
trait loci does as yet not offer a resolution high enough to exactly define the 
responsible gene loci. Thus, the overall extent to which overdominant genes 
contribute to the phenomenon of inbreeding depression remains unclear, as it has not 
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been possible so far to identify single responsible genes and draw conclusions upon 
the extent of their effects. 
It has been proposed that inbreeding can purge deleterious alleles when it is combined 
with selection pressure (Boakes et al. 2007; McParland et al. 2009), thereby avoiding 
the phenomenon of inbreeding depression. A notable example supporting this 
hypothesis is a study of the Chillingham cattle in Northern England. This herd of 93 
(www.chillinghamwildcattle.com 2010) animals is genetically almost uniform as it 
has experienced no additions to its genetic pool in at least 300 years. Studies of blood 
groups and biochemical polymorphisms as well as microsatellite markers known for 
their polymorphisms in cattle (Visscher et al. 2001), demonstrated that the 
homozygosity of this herd far exceeds that of other cattle breeds or wild species. The 
continuing viability of this herd (animal numbers rose from 49 in 2000 to 93 in 2010) 
is seen as evidence for purging of deleterious alleles. 
Heterosis is often described as the opposite of inbreeding depression (Glodek in 
Kräußlich 1994). This effect occurs as a result of outbreeding. Crossing individuals of 
two inbred lines or separate populations (for example two breeds) will lead to 
offspring that, on average, possesses greater fitness than the parent generation did 
(Brem in Kräußlich and Brem 1997). Analogously to inbreeding depression theory, 
this effect is attributed to a shift in allele distribution, in the case of heterosis in an 
increase in heterozygosity in the offspring generation. Again, as with inbreeding 
depression, the two concepts of partial dominance and overdominance have been 
employed in elucidating the genetic basis for heterosis (Charlesworth and Willis 
2009). 
 
2.4.3 Inbreeding in pig livestock and experimental animals 
 
Animal genetic resources have contracted dramatically over the past decades, 
especially in areas of great economic importance and vast commercial impact such as 
the pig livestock industry (Welsh et al. 2010). As the number of core swine breeds 
employed in meat production has decreased, selection for highly specific productivity 
traits within these breeds has intensified at the same time. Meuwissen and Woolliams 
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(1994) suggest that fitness of offspring may decrease either due to inbreeding 
depression or as a negatively correlated response to artificial selection. According to 
Bereskin et al. (1968) the so-called margin-of-safety effect appears to provide a 
certain amount of resistance against the detrimental effects of homozygosity in the 
lower levels of inbreeding in pigs. This, however, does not apply to inbreeding levels 
beyond approximately 10%. When Donald (1955) gave an account on data drawn in 
Britain on the effect of inbreeding pig lines of the Large White breed, several 
productive and reproductive characteristics were shown to be negatively influenced by 
inbreeding. Abnormalities in new born piglets, for example, were about twice as 
prevalent in the inbred lines as they were in the outbred controls. Similarly, litter 
parameters deteriorated with increased inbreeding. Elaborating on this, Bereskin et al. 
(1968) differentiated between the effect inbreeding in the sire, dam or litter has on 
reproductive performance. While an inbred sire was shown to be of little consequence 
for litter size at farrowing, inbreeding in the dam significantly depressed not only litter 
size, but also average piglet weight and total litter weight. On the other hand, the 
inbreeding in the litters themselves effected an increased influence on weaning traits 
rather than on farrowing. 
Closed swine breeding company nucleus herds supplying animal breeding stock for 
commercial swine producers undergo intense selection for specific traits (Rathje 
2000), leading to greater likelihoods of elevated inbreeding levels that hamper 
productivity and are subsequently transferred to commercial pork production herds. 
For the European swine population, Laval et al. (2000) examined 11 European pig 
breeds with respect to their genetic diversity using microsatellite markers. They 
observed a strong clustering into individual breeds, each with a common genetic 
background, and significantly reduced heterozygosity in the case of the German 
Landrace breed as well as in the Swabian-Hall breed. Consanguineous mating, 
heightening inbreeding levels, is proposed as the likely cause for these findings. In a 
follow-up project, San Cristobal et al. (2006) presented data on a total of 58 European 
pig breeds and lines confirming and elaborating on the previously published material. 
Similarly, a study of Welsh et al. (2010), who analysed the pedigree of five swine 
breeds in the United States, reported that, presently, more than 99% of the surveyed 
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pigs are inbred. The majority display inbreeding coefficients of less than 10% but a 
notable exception was found in Landrace pigs, which feature a mean inbreeding 
coefficient of almost 18%. An earlier work of Hubbard et al. (1990) determined the 
rates of inbreeding in a number of performance tested breeds in Canada in the 1970s 
and 80s. They found increasing numbers of inbred animals in each of the tested herds 
as well as rising average inbreeding coefficients over the years.  
Today, the intense selection pressure and competition within the swine industry makes 
strategies for controlling the accumulation of inbreeding ever more important (Rathje 
2000). Blackburn and Welsh (2010) conclude that the actions of breeders are the key 
in managing the extent of inbreeding because it is within their scope to determine 
which animals to mate to one another in order to reach the best possible equilibrium 
between productivity and selection for other traits. Even though the avoidance of 
matings between close relatives does not lower the eventual rate of inbreeding within 
a herd, it nevertheless delays it (Meuwissen 2009). The frequently occurring shifts in 
breeding objectives may also contribute to delaying inbreeding in commercially 
exploited pig breeds even further. 
Experimental pig herds, on the other hand, are used as resource populations to supply 
animals for biomedical research. Initiation of those herds and selection for required 
traits usually resulted from comparably small animal numbers. For example, a Sinclair 
miniature swine herd susceptible to the development of cutaneous malignant 
melanoma (Gomez-Raya et al. 2008) originated from only 10 animals. Similarly, the 
founding animals of Göttingen miniature pigs were a group of 16 Minnesota miniature 
and Vietnamese potbellied pigs (Simianer and Kohn 2010). The main breeding 
objective usually includes a very clearly defined physiological parameter such as body 
weight (Dettmers et al. 1965; Panepinto and Phillips 1981; Kohn et al. 2008) that is 
being selected for, or a certain genetic property for which populations need to be kept 
fairly closed in order to maintain the desired trait. In small populations this often 
results in a continuous increase in inbreeding and loss of alleles (Simianer and Kohn 
2010) similar to that of closed seed stock herds in commercial pig production.  
Reproductive capacity may be further impaired by a genetic and physiological 
antagonism between litter size and body weight. In a study analysing the 
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developmental capacity of cloned embryos, Koo et al. (2009) found that genes related 
to implantation and maintenance of pregnancy were significantly down-regulated in 
miniature pig fetuses compared to domestic pigs. In earlier experiments Diehl et al. 
(1986) had already concluded that the comparably small litters of miniature pigs are 
due to lower ovulation rates and an unfavourable uterine environment not wholly 
attributable to a depression originating in the 40% inbreeding coefficient of the 
examined miniature pig herd.  
From an experimental viewpoint, variations in the genetic background of animals 
constitute factors that contribute to heterogeneity of experimental results (Sachs in 
Swindle 1992). Inbred strains of rodents are defined by at least 20 consecutive 
brother-to-sister matings resulting in homozygosity close to 100%. In mice, the 
resulting inbreeding depression has been shown to be most evident in intermediate 
generations (Issa and Seeland 2001) with inbreeding coefficients of around 40%. Over 
time, selection for fitness and reproductive capacity may offset the negative effect an 
increasing inbreeding coefficient has. Certain miniature swine herds have been 
established as highly inbred lines (Mezrich et al. 2003; Wang et al. 2006). However, 
fertility problems make reproduction in these herds a trying venture. A SLA 
homozygous miniature pig line first reported on by Sachs et al. (1976) has reached 
inbreeding levels greater than 90% (Mezrich et al. 2003; Cho et al. 2007). Data on 
their reproductive performance in 1992 already showed average litter sizes that were 
reduced to 4.5 piglets per sow (Koketsu et al. 1994). Similarly, an inbred herd of 
Westran pigs with an estimated inbreeding coefficient of 98% (O’Connell et al. 2005) 
has average litters of only 4 piglets. For domestic pig breeds Soe et al. (2008) also 
report on deteriorating reproductive performance in the establishment of a highly 
inbred SLA homozygous Duroc pig line. In a review on pigs utilised in 
xenotransplantation settings, d’Apice and Cowan (2009) pointed out that most groups 
that had generated GalKO pigs found that breeding these animals to homozygosity for 
this gene and establishing a GalKO herd proved difficult because the inbreeding 
necessary to achieve this resulted in very low fertility.    
Consequently, breeding management of experimental pig herds must pursue the 
conservation of the desired physiological or genetic characteristics but it must also 
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include the goal of keeping enough genetic variation within the population in order to 
maintain a satisfactory reproduction level (Prather et al. 1997; Wang et al. 2006; 
Gomez-Raya et al. 2008; Simianer and Kohn 2010). 
 
 
2.5 Selection of breeding material – expression analysis 
 
Producing transgenic pigs by any of the earlier mentioned techniques, resulting in 
germline stability of the transgene in the genome, offer the opportunity to expand 
transgenic pig herds by means of natural reproduction. Additive gene transfer entails 
random integration of the transgene, thus leading to the possibility of an integration 
site influence on the expression potential of the transgene. In a first step, breeding 
schedules for transgenic pigs therefore require the identification of founder animals 
with appropriate transgene expression. Taking into account the potential of multiple 
integration loci and the resulting segregation during breeding, founder animals ideally 
carry only one integration site, necessitating genomic analysis in addition to 
expression profiles. In contrast to site-directed mutagenesis, the unpredictability of 
integration sites in additive gene transfer effects unknown endogenous genomic 
flanking regions of the transgene. Several possibilities exist for clarifying the adjacent 
genomic sequence.  
Chromosome-walking based polymerase chain reactions (PCR) for DNA fragment 
walking adjacent to known sequences are available as different approaches. Inverse 
PCR (Ochman et al. 1988; 1990) or ligation-mediated PCR (Dai et al. 2000) are both 
based on genomic DNA fragmented by restriction digest. The first uses two specific 
primers that bind on the transgene sequence and face apart on the genomic DNA but 
subsequently face towards each other after circularisation by ligation. The latter uses 
only one transgene-specific primer as well as a primer binding on a synthetic adapter 
which is ligated to the genomic DNA fragments after digestion. Both methods have 
their limitations, mainly due to the unpredictable length of the genomic fragments and, 
especially in the case of the adapter-based method, amplification of unspecific 
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fragments. The use of nested PCR overcomes these limitations at least partially. 
Further methodological improvements have been presented (Ren et al. 2005; Bryda et 
al. 2006; Liang et al. 2008), but in all cases the increase in efficiency is paid for by a 
significant rise in effort. An alternative approach avoiding the unpredictable length of 
genomic DNA fragments has been described by Liu and Whittier (1995). The method 
is based on significantly different annealing temperatures of the primers used. In 
sequential steps, the high melting and transgene-specific primer is used for linear and 
single strand amplification of the transgene plus adjacent region, whereas the 
complementary strand is synthesised in a later step using the annealing of degenerate 
primers at lower temperatures. Several rounds of this procedure using semi-nested 
PCRs shift the proportion of unspecific amplicons to that of defined length towards 
the latter, again making the attainment of specificity a laborious process. 
Libraries of bacterial artificial chromosomes (BACs) covering the genome of the 
founder animals constitute a different approach in clarifying transgene integration 
sites. This method relies on the cloning of large genomic DNA fragments into plasmid 
vectors and their multiplication in bacteria. By generating probes that recognise the 
transgene sequence, it then becomes possible to identify the BACs that carry the 
transgenic DNA, sequence them and thereby identify the surrounding genomic DNA 
sequence. Construction of porcine BAC libraries is being conducted regularly (Liu et 
al. 2010; Suzuki et al. 2000), however, the intense effort this technique involves 
makes it feasible only on the small scale. Analysis of large numbers of different 
transgenic lines would be extremely time consuming, as the whole procedure has to be 
repeated for each individual founder animal. 
Whole genome sequencing involves whole genome amplification of limited DNA 
quantities and the subsequent sequencing using high-throughput techniques (Coskun 
and Alsmadi 2007). Currently, this method is mainly used in preimplantation 
diagnostics (Zheng et al. 2011), but has also found application in population genetics 
(Pool et al. 2010). Alignment of amplified and sequenced whole genomic DNA with 
genome databases can determine transgene integration sites. Different techniques for 
amplifying the genomic DNA are being routinely utilised. Primer extension 
preamplification (PEP) (Zhang et al. 1992; Dietmaier et al. 1999) and degenerate 
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oligonucleotide primed PCR (DOP-PCR) (Telenius et al. 1992) both rely on thermal 
cycling using Taq polymerase. Multiple displacement amplification (MDA), on the 
other hand, is an isothermal method dependent on bacteriophage phi29 DNA 
polymerase (Dean et al. 2002). In contrast to the former methods, this polymerase 
offers better proofreading activity, making preferential amplification of one allele or 
random amplification failure of alleles (allele drop out) less likely. Further 
improvements in the accuracy of whole genome amplification are currently being 
discussed (reviewed in Zheng et al. 2011). High-throughput sequencing technology is 
then necessary to master the huge amounts of data derived from whole genome 
amplification. A variety of systems such as pyrosequencing or reversible terminator 
technology are already in use (reviewed in Kircher and Kelso 2010), with new 
developments constantly increasing efficiency. Initial studies demonstrated the proof 
of principle for whole genome sequencing in the determination of ENU-induced 
mutations in mice as well as in C. elegans (Flibotte et al. 2010; Arnold et al. 2011). 
Applications in integration site determination of transgenes, however, currently find 
their limit in the high costs involved in this technique as well as in the availability of 
comprehensive sequencing data for the genome of the species in question, or lack 
thereof. For the pig, the Swine Genome Sequencing Consortium initiated a whole 
genome sequencing project in 2006 (Chen et al. 2007) which has been underway 
since. Archibald et al. (2010) report on the preliminary release of an annotated draft 
sequence but so far no whole porcine genome sequence has been made available. 
Whole genome amplification is therefore currently not an option in clarifying 
transgene integration sites in the pig. 
Expression analysis focuses either on the RNA or the protein level. While the latter is 
more significant for the performance of the transgene, the RNA level is easier to 
determine and to quantify. Although RNA is a much less stable poly-ribonucleic acid 
compared to DNA, isolation of transcripts have been described decades ago (Chirgwin 
et al. 1979, Han et al. 1987). First quantification experiments were performed by 
Northern blotting (Alwine et al. 1977; 1979) which was developed analogously to the 
DNA analysis described by Southern (Southern 1975). However, a more systematic 
and precise quantification has become available by the combination of reverse 
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transcription and PCR (RT-PCR) (Han et al. 1987, Simpson et al. 1988). By using 
viral reverse transcriptase enzymes, complementary DNA (cDNA) is synthesised that 
constitutes a suitable template for PCR amplification. Several steps have improved 
this method from a semi-quantitative approach that evaluated one single sample per 
reaction to a technique that quantifies the sample more precisely, and eventually to an 
application addressing the expression levels of the whole transcriptome on one single 
chip (Schena et al. 1995). Transcriptome analysis has thus evolved to an automatised 
high-throughput technology for expression analysis. However, in contrast to 
quantification of expression levels, the localisation of expression is more difficult to 
achieve in transcriptome analysis. Even though hybridisation of tissue sections with 
labelled probes has long been employed, the technology is still laborious, time-
consuming and error prone (Coghlan et al. 1985). Additionally, biological limitations 
have to be taken into account. As the action of a given gene conventionally takes place 
at the protein level, the transcription status gives only limited information about the 
protein activity. Numerous post-transcriptional regulatory mechanisms, such as 
mRNA stability, translational control, intra-cellular protein trafficking or protein 
activation/de-activation are essential, too. 
From the technological point of view, the protein level is much more complicated to 
address than the RNA level. In contrast to RNA, which represents a homogenous pool 
of poly-ribonucleic acids with almost identical biochemical features, proteins are more 
diverse regarding their solubility, their sensitivity for degradation and their 
accessibility for detection. Even more, whereas RT-PCR represents a powerful tool 
for detection of even low amounts of particular molecules, such an amplification 
technology does not exist for proteins, limiting the sensitivity of protein analysis. 
Antibody based detection methods such as Western blotting, immunohistochemistry, 
enzyme-linked immunosorbent assay (ELISA) or fluorescence-activated cell-sorting 
(FACS) are the most widely employed applications. While Western blotting has 
evolved as a routine technology in many laboratories for detection or semi-
quantification of differently sized proteins, or the study of their glyocosylation 
patterns (Renart et al. 1979), immunohistochemistry addresses the cellular, or even 
sub-cellular localization of specific proteins (reviewed in Ramos-Vara 2005). ELISA 
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has been established as the most reliable quantification method for particular proteins 
from tissue samples (Engvall and Perlmann 1971) whereas FACS was developed for 
protein analysis on the surface of cells in liquids (Sugarbaker et al. 1979).  
Alternative methods for protein analysis have emerged over the last decade, aiming 
for increased sensitivity and a higher throughput. While microarrays address the 
analysis of whole proteome samples by an antibody based means (reviewed in Lopez 
and Pluskal 2003), sensitivity of protein analysis has been increased by implementing 
the principle of mass-spectrometry detection (Sickmann et al. 2002). However, both 
approaches, similar to advanced RNA-technologies, require cost-intensive equipment 
and profound know-how. Genomic and transcriptome or proteome analyses thus 
provide diverse possibilities for examining potential founder animals with respect to 
their suitability for breeding transgenic pig lines.  
 
Since continuous reproduction of transgenic pigs by cloning had proven itself as too 
inefficient in terms of animal numbers that can reasonably be generated by it, the aim 
of this thesis was to identify novel transgenic founder animals by genomic and 
expression analysis to subsequently re-establish them by cloning for utilisation in 
breeding.  
Concurrently, already existing transgenic founder pigs for xenotransplantation were to 
be expanded into multitransgenic breeding herds while accounting for the two 
conflicting issues of transgene segregation and rising inbreeding coefficients.
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3 ANIMALS, MATERIALS AND METHODS 
 
3.1 Animals 
 
In this work genetically engineered pigs displaying the following modifications to 
their genome were investigated and used for the establishment of transgenic breeding 
herds. All animal experiments were carried out in compliance with the German 
Animal Protection Law (AZ: 211-2531-58/97 and AZ: 55.2-1-54-2531-54/08, 
Regierung von Oberbayern). 
3.1.1 GalKO 
Original founder animals of the Large White breed were established at Revivicor Inc., 
Blacksburg, VA. As described in detail in Dai et al. (2002) and Phelps et al. (2003), 
targeting of the catalytic domain in exon IX of the α1,3-galactosyl-transferase gene by 
homologous recombination initiated a loss of gene function. This was achieved by 
using a targeting vector consisting of two homologous arms of 4.9 kb and 1.9 kb, 
respectively. Targeting efficiency was increased by promoter trapping with an IRES-
neo-polyadenylation cassette. Somatic cell nuclear transfer (SCNT) and embryo 
transfer (ET) yielded founder animals. 
3.1.2 CD46 
CD46 transgenic pigs were established by Loveland et al. (2004). The transgene 
vector was assembled from a genomic human CD46 fragment containing exons I and 
II as well as a cDNA fragment of exons III-XII and a SV40 polyadenylation site. This 
CD46 minigene was used for pronuclear microinjection into fertilised oocytes which 
were subsequently transferred to oestrus-synchronised recipients. These CD46 
transgenic pigs were mated to homozygous GalKO pigs at Revivicor Inc., Blacksburg, 
VA, generating double transgenic founder animals (Hara et al. 2008). Primary cells of 
a double transgenic boar were transferred to the Chair of Molecular Animal Breeding 
and Biotechnology, LMU Munich. These cells were subsequently used for SCNT 
according to the protocol of Kurome et al. (2006) and, following that, ET into oestrus-
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synchronised German Landrace gilts as described in Besenfelder et al (1997). First 
cloned GalKO/CD46 founders were born at the Moorversuchsgut (MVG), Badersfeld 
in 2006. Nuclear transfers as well as embryo transfer experiments at the MVG were 
performed by Dr. Mayuko Kurome and Dr. Barbara Kessler. Cloned offspring has 
since been used for xenotransplantation experiments and for the establishment of the 
breeding herd.  
3.1.3 hTM 
The transgene vectors for human thrombomodulin (hTM) were established at the 
Chair for Molecular Animal Breeding and Biotechnology, LMU Munich and have as 
of now not been published yet. The DNA constructs consist of a 6 kb porcine 
thrombomodulin promoter, the coding sequence of human thrombomodulin, a poly-
adenylation cassette from the bovine growth hormone gene and a neomycin or 
blasticidin resistance cassette for positive selection. The hTM-neo construct (Figure 
3.1 (A)) was transfected into primary kidney cells from a wild-type German Landrace 
boar, whereas the hTM-bla construct (Figure 3.1 (B)) was transfected into primary 
kidney cells of a neomycin resistant GalKO/CD46 transgenic boar cloned from the 
above described Revivicor cells. Both types of hTM-transgenic cells were then used 
for SCNT and subsequent ET into oestrus-synchronised German Landrace gilts as 
described above in order to generate hTM and GalKO/CD46/hTM transgenic boars. 
Vectors were constructed by Dr. Nikolai Klymiuk and cell culture experiments were 
performed by Dr. Annegret Wünsch, both at the MVG. 
3.1.4 HLA-E 
Human leukocyte antigen (HLA)-E transgenic pigs were established by Weiss et al 
(2009) using a 7.7 kb genomic fragment of HLA-E with a HLA-B7 signal sequence 
and a 15 kb genomic human β2 microglobulin fragment. Both vectors were 
microinjected simultaneously into the pronucleus of zygotes with which ET to 
oestrus-synchronised recipient gilts was performed. Transgenic founder animals were 
generated at the MVG, Badersfeld in 2002 according to the methods described in this 
publication. These pigs have been reproduced at the MVG by breeding since. 
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3.1.5 LEA29Y 
Pigs expressing the CTLA4-Ig derivate LEA29Y were generated at the Chair for 
Molecular Animal Breeding and Biotechnology, LMU Munich. The coding region of 
LEA29Y was commercially synthesised (Bio&Sell, Nürnberg). For ubiquitous 
expression LEA29Y was inserted into an expression cassette between the CAG-
promoter and the rabbit haemoglobin beta polyadenylation box according to Matsuda 
and Cepko (2004) (Figure 3.1 (C)). For beta-cell-specific expression LEA29Y was 
placed under a 1.3 kb insulin promoter and linked to a poly-adenylation cassette 
derived from the bovine growth hormone (Grzech et al. 2010) (Figure 3.1 (D)). A 
neomycin resistance cassette facilitates positive selection of transgenic cells in both 
cases. Vectors were designed and constructed by Dr. Nikolai Klymiuk at the MVG, 
Badersfeld. Transgenesis of primary cells, nuclear transfer as well as embryo transfer 
were performed analogously to the procedures described for the hTM constructs.  
 
Figure 3.1: DNA constructs for establishment of novel transgenic pig lines. hTM 
constructs contain either a neomycin resistance for transfection into wild-type cells (A) or a blasticidin 
resistance for transfection into GalKO/CD46 background (B). Both LEA29Y constructs are neomycin 
resistant; a CAG promoter is used for ubiquitous expression (C) and an insulin promoter for β-cell 
specific expression (D). Primer binding sites for genotyping are illustrated by arrows; localisation of 
probes for Southern blotting is indicated by bars and the relevant restriction sites are shown.  
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3.2 Materials 
3.2.1 Chemicals 
All chemicals were used in p.a. quality unless noted otherwise. 
 
Acetic acid (glacial)      Merck, Darmstadt 
Agar-agar       Roth, Karlsruhe 
Agarose Universal      Bio&SELL, Nürnberg 
Agarose UltraPureTM       Invitrogen, Karlsruhe 
Ampicillin        Roth, Karlsruhe 
Bromophenolblue      Roth, Karlsruhe 
Chloroform (Trichlormethan)    Merck, Darmstadt 
D-Mannitol       Sigma, Steinheim  
DTT (Dithiothreitol)      Biomol, Hamburg 
EDTA (Ethylenediaminetetraacetic acid)   Roth, Karlsruhe 
Ethanol       Roth, Karlsruhe 
Ethidiumbromide (1mg/ml)     Merck, Darmstadt 
Formaldehyde solution, 37%     Roth, Karlsruhe 
Formamide       Roth, Karlsruhe 
Glucose       Roth, Karlsruhe 
Glycerol       Roth, Karlsruhe 
Hydrochloric acid, 37%     Roth, Karlsruhe 
Isoamylalcohol      Roth, Karlsruhe 
Magnesium chloride      Merck, Darmstadt 
Paraformaldehyde      Merck, Darmstadt 
PEG 8000       Roth, Karlsruhe 
Peptone/Tryptone      Roth, Karlsruhe 
Phenol        Roth, Karlsruhe 
Phosphoric acid      Roth, Karlsruhe 
PIPES (Piperazin-1,4-bis-(2-ethansulfonic-acid))  Sigma, Steinheim  
Potassium acetate      Roth, Karlsruhe 
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Potassium chloride      Sigma, Steinheim 
2-Propanol       Roth, Karlsruhe 
SDS (Sodiumdodecylsulfate), ultrapure   Roth, Karlsruhe 
Sodium acetate-trihydrate     Merck, Darmstadt 
Sodium chloride      Roth, Karlsruhe 
tri-Sodium citrate-2-hydrtae     Roth, Karlsruhe 
Sodiumdihydrogenphosphate-1-hydrate   Merck, Darmstadt 
di-Sodiumhydrogenphosphate-2-hydrate   Roth, Karlsruhe 
Sodium hydroxide (2N)     Roth, Karlsruhe 
D(+)-Sucrose       Roth, Karlsruhe 
Sulfuric acid       Sigma, Steinheim 
Tris (Tris-(hydroxymethyl)-aminomethan)   Roth, Karlsruhe 
Tween® 20       Sigma, Steinheim 
Yeast extract       Roth, Karlsruhe  
 
3.2.2 Consumables 
ABgene® PCR plates, 96-well    Thermo Scientific, UK 
Centrifuge tubes (15ml, 50ml)  Falcon®, Becton Dickinson, 
Heidelberg 
Coated filter paper  Roth, Karlsruhe 
Culture dishes       Roth, Karlsruhe 
Developing and fixing solutions for x-rays AGFA-Gevaert N.V., 
Belgium 
Hybond-N+ nylon membrane GE Healthcare, Munich 
Maxisorp 96-well immuno plates    NuncTM, Denmark 
Parafilm® M American Can Company, 
USA 
PCR reaction tubes (0.2ml)     Braun, Wertheim 
Pipet tips       Eppendorf, Hamburg 
Pipet tips with filter      Axygen Inc., USA  
SafeGrip® Latex gloves     SLG, Munich 
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Safe-Lock reaction tubes (1.5ml, 2ml)   Eppendorf, Hamburg 
Saran Barrier food wrap     Dow, USA 
Self-adhesive plastic covers     NuncTM, Denmark 
Sephadex G-50 columns      Amersham, UK 
Super RX Fuji medical x-ray film  FujiFilm Corp., Japan 
Whatman paper       Roth, Karlsruhe 
 
3.2.3 Devices 
AccuJet® pro Pipetman     Brand, Wertheim 
Agarose gel electrophoresis chamber   OWL Inc., USA 
Centrifuge 5415 D      Eppendorf, Hamburg 
Centrifuge 5417 R      Eppendorf, Hamburg 
Chyo scales        YMC Co., Japan 
Glass tubes 80mm      Zefa, Harthausen 
Eppendorf HH Mastercycler Gradient   Eppendorf, Hamburg 
GeneQuant Pro spectrophotometer    Amersham, UK  
Gel documentation system     BioRad, Munich  
GFL 3031 shaker      Hilab, Düsseldorf 
Glass pipets       Hirschmann, Eberstadt 
Hybrid mini 38 hybridisation oven    H. Saur, Reutlingen 
37°C incubator       Memmert, Schwabach 
60°C incubator       Memmert, Schwabach 
Labofuge M centrifuge Heraeus, Osterode 
Microprocessor pH meter WTW, Weilheim 
MS1 minishaker  IKA Labortechnik, Staufen 
Multitip pipet (300µl) Eppendorf, Hamburg 
Pipets (1000µl, 200µl, 20µl)     Gilson Inc., USA 
Polytron homogeniser Kinematica, Switzerland 
Power Pac 300 gel electrophoresis unit   BioRad, Munich 
REAX2 Automatic swivel unit     Hilab, Düsseldorf 
RH Basic heating plate with magnetic stirrer IKA Labortechnik, Staufen 
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Severin 900 microwave     Severin, Sundern 
Tecan Sunrise ELISA reader with Magellan software Tecan, Austria 
Thermomixer 5436      Eppendorf, Hamburg 
UV cross-linker  Vilber-Lourmat, France 
Varioklav 400 autoclave H+P Labortechnik, 
Oberschleißheim 
WB6 water bath Firmengruppe Preiss-
Daimler, Medingen 
X-ray cassette Rego, Augsburg 
 
3.2.4 Antibodies, drugs, enzymes, oligonucleotides, standards 
3.2.4.1 Antibodies 
 
Primary antibodies 
Polyclonal rabbit anti-human IgG    Dako, Denmark 
 
Secondary antibodies 
Polyclonal rabbit anti-human IgG/HRP   Dako, Denmark 
 
3.2.4.2 Drugs 
Azaperon (Stresnil®) Janssen Pharmaceutica, 
Belgium 
Ketamine hydrochloride (Ursotamin®)   Serumwerk Bernburg, 
Bernburg 
T61 Intervet, Unterschleissheim 
 
3.2.4.3 Enzymes 
BigDye®  Terminator v3.1 Applied Biosystems, 
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Weiterstadt 
Herculase® II and buffer (5x)     Agilent, Böblingen 
Klenow fragment exo-  (5U/µl) and buffer (10x) Fermentas, St. Leon Roth 
Taq Polymerase (5U/µl) and buffer (10x) Agrobiogen, 
Hilgertshausen 
Proteinase K (20mg/ml)     Roth, Karlsruhe 
Restriction enzymes and recommended buffers:  Fermentas, St. Leon Roth 
Alw44I         
BamHI 
EcorI 
HindIII 
NcoI 
PstI 
PvuII 
TaqI 
XbaI  
Ribonuclease A (RNase A) (0.2U/µl)   Roche, Mannheim 
T4 DNA Ligase (2000U/µl) and buffer (10x) Fermentas, St. Leon Roth 
 
3.2.4.4 Oligonucleotides       
Thermo Scientific, UK 
 
CD46ex2F  5-GGC TAC CTG TCT CAG ATG AC-3 
CD46ex3R  5-CCA TTT GCA GGG ACT GCT TG-3 
GGTAr21  5-GCC ACC TCT TCT CGG ACT TGA TCT C-3 
GGTAf22  5-CAT CCA GGC ACA TAC AGC ACA AG-3 
hTMf1a  5-CTT CAT GGC ATT TC-3 
hTMf1b  5-TGC TAG TCA ATC TT-3 
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hTMf2a  5-GTG ACC ATG GCT TT-3 
hTMf2b  5-AGC TCT GAT TCA AC-3 
hTMs3f  5-TTG GAA GTT CCT GGG ACA GAG-3 
hTMs6f  5-GGT TTC AGG TTC GAT TCC TG-3 
hTMf21  5- GGC CAT AAC TGA CAT CCC GTT C-3 
hTMf22  5-ACA GTC ACA GAG TTG CCT CTG C-3 
hTMf23  5-GAA TCC CAG CCA CAG CTT TGA C-3 
hTMf24  5-TGG ATG AAC TCA GAC CAA ACA G-3 
hTMf25  5-GAG ATG GAC TGG CCC TCT GCA AG-3 
hTMf26  5-GAC AGT GAT GGA CAG CCG ACG GCA G-3 
hTMf27  5-CGA CAG GTG CTT CTC GAT CTG-3 
hTM43f1  5-CAG TGT TTG TCT TCT TAA CTA TC-§ 
hTM1101f  5-CGA CGC AGT CCT GCA ACG A-3 
hTMr1   5-CAG CTA TCC TGA AC-3 
hTMr2   5-AGC GCC TTT ATC CT-3 
hTM44r1  5-ATC ACT ATG TCA TTC AAG AGC TC-3 
hTM44r4  5-TCG TTT CTG TCC AAA ACC AGA AG-3 
hTM1608r  5-CCG GAG TCA CAG TCG GTG CCA A-3 
hTM-pA2050r 5-GGG CAA ACA ACA GAT GGC TG-3 
hTM-pA2100r 5-AAA GGA CAG TGG GAG TGG CA-3 
pTMSr  5-AAG CGC ACC AGC TGA AAG-3 
neokanf  5-GAC AAT AGC AGG CAT GCT G-3 
neokanR  5-GTG GAT GTG GAA TGT GTG C-3 
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bla241r  5-TTC CGA TCG CGA CGA TAC AAG TCA G-3 
bla343r  5-GCT GTC CAT CAC TGT CCT TCA CT-3 
PGKr   5-GCT GCT AAA GCG CAT GCT CCA GAC-3 
bGHpAf1  5-AGG TGC CAC TCC CAC TGT CTT TTC-3 
bGHpAr3  5-GAT GGC TGG CAA CTA GAA GGC AC-3 
bGHpAr4  5-GTC GAG GCT GAT CAG CGA GCT C-3 
CAGf   5-CTC TGC TAA CCA TGT TCA TG-3 
Neof   5-TGA TTC CCA CTT TGT GGT TC-3 
NeoPf   5-CAG CTG TGC TCG ACG TTG TC-3 
HLAE-f  5-CCC AAG TGA AAT ACC CTG GCA-3 
HLAE-r  5-CGA AGA TTC CCT GAC AAT CCC-3 
LEAf   5-CCA GCA CCT GAA CTC CTG-3 
LEAr   5-GGC TTT GTC TTG GCA TTA TG-3 
pACTB954f  5-CGC TCG TGG TCG ACA ACG-3 
pACTB1919r  5-CTG GAT GGC CAC GTA CAT G-3 
 
3.2.4.5 Protein standards 
Bovine serum albumin (BSA) Fraction V   Roth, Karlsruhe 
Human serum protein calibrator    Dako, Denmark 
 
3.2.5 Buffers, media, solutions 
Water, deionised in a Millipore machine (EASYpure® II, pure Aqua, Schnaitsee) and 
termed aqua bidest., was used as solvent, unless indicated otherwise. 
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Chloroform-isoamylalcohol (CiA) 
96 ml chloroform 
4 ml isoamylalcohol 
Stored at 4°C protected from light 
 
DNA loading buffer (10x) 
10% glycerol in aqua bidest. 
1 spatula tip of bromophenolblue 
Add 0.5 M NaOH until colours turns blue 
Stored aliquoted at 4°C 
 
dNTP-mix 
2 mM dATP, dCTP, dGTP, dTTP   
in aqua bidest. 
Stored aliquoted at -20°C 
 
ELISA coating buffer 
0.35 g NaH2PO4, H2O 
1.34 g Na2HPO4, 2H2O 
8.47 g NaCl 
Ad 1000 ml aqua bidest. 
Adjust pH to 7.2 with 5M NaOH 
Stored at 4°C 
 
ELISA dilution and washing buffer 
0.35 g NaH2PO4, H2O 
1.34 g Na2HPO4, 2H2O 
29.22 g NaCl 
Ad 1000 ml aqua bidest. 
1 ml Tween 20 
Adjust pH to 7.2 with 5M NaOH 
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Stored at 4°C 
 
ELISA stop solution 
0.5 M Sulphuric acid 
Stored at room temperature 
 
LB medium 
5 g yeast extract 
10 g peptone/tryptone 
5 g NaCl 
Ad 1000 ml aqua bidest. 
pH 7.0 (adjust with 5 M NaOH) 
autoclave 
Medium was stored at room temperature. 
 
LB-agar plates 
1000 ml LB pH 7.0 
15 g agar-agar 
Autoclave 
Cool to 50°C 
Add 1 ml ampicillin (500 mg/ml) 
Pour into sterile 10 cm culture dishes  
After setting, plates were stored at 4°C. 
 
4% Paraformaldehyde in 0.1 M Phosphate Buffer 
1. Prepare 0.2 M Phosphate Buffer (PB), pH 7.4: 
21.8 g Na2HPO4 
6.4 g NaH2PO4 
Ad 1000 ml aqua bidest. 
Adjust pH with 5 M NaOH 
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2. Prepare 0.1 M PB pH 7.4: 
500 ml 0.2M PB 
Ad 1000 ml aqua bidest. 
40 g paraformaldehyde was added to 1000 ml 0.1 M PB, pH 7.4 and heated to 60-
65ºC while stirring under the hood. A few drops of 1 N NaOH cleared the solution. 
After cooling the solution was filtered and stored at 4°C. 
 
PEG-MgCl2 
40% (w/v) PEG 8000 
30 mM MgCl2 
Stored at room temperature 
 
Phenol-chloroform-isoamylalcohol (PCiA) 
25 ml phenol 
25 ml CiA 
Stored at 4°C protected from light 
 
Plasmid A 
50 mM glucose 
25 mM Tris/HCl pH 8.0 
10 mM EDTA/NaOH pH 8.0 
Stored at room temperature 
 
Plasmid B 
0.1 M NaOH 
0.5% (w/v) SDS 
Prepare freshly 
 
Plasmid C 
3 M KOAc 
pH 4.8 with 9 M HOAc 
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autoclave  
Stored at room temperature 
 
Sequencing buffer (5x) 
17.5 ml 1 M Tris/HCl (pH 9.0) 
125 µl 1 M MgCl2 
Ad 50 ml aqua bidest. 
Stored aliquoted at -20°C 
 
Sodium-phosphate Buffer 1M 
4 ml 85% H3PO4 
89 g Na2HPO4, 2H2O 
Ad 1000 ml aqua bidest. 
 
Southern Blot Church buffer 
1% BSA 
1 mM EDTA, pH 8.0 
500 mM Sodium-phosphate Buffer pH 7.2 
7% SDS 
 
Southern Blot depurination solution 
0.3M HCl 
 
Southern Blot high stringency buffer 
1 mM EDTA, pH 8.0 
40 mM Sodium-phosphate Buffer pH 7.2 
1% SDS 
 
Southern Blot low stringency buffer 
0.5% BSA 
1 mM EDTA 
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40 mM Sodium-phosphate Buffer pH 7.2 
5% SDS 
 
Southern Blot neutralisation solution 
0.5 M Tris 
1.5 M NaCl 
pH 7.5 
 
Southern Blot 20x SSC 
0.3 M Na-Cit 
3 M NaCl 
 
Southern Blot strand break solution 
0.5 M NaOH 
1.5 M NaCl 
 
STE 
10 mM Tris/HCl pH 8.0 
0.1 M NaCl 
1 mM EDTA/NaOH pH 8.0 
Stored at room temperature 
 
TAE buffer (50x) 
242 g Tris 
100 ml 0.5M EDTA (pH8.0) 
57 ml AcOH 
Ad 1000 ml aqua bidest 
Buffer was stored at room temperature and diluted to single concentration with aqua 
bidest. for use. 
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10 mM Tris/HCl pH 8.0 
10 mM Tris 
Adjust pH to 8.0 with HCl 
Stored at room temperature 
 
3.2.6 Kits 
CloneJETTM PCR Cloning Kit    Fermentas, St. Leon Rot 
NexttecTM Genomic DNA Isolation Kit    Nextecc, Leverkusen 
Qiaex® II Gel Extraction Kit     Qiagen, Hilden 
Roti®-Quant       Roth, Karlsruhe 
 
3.2.7 Others 
α
32P-dCTP  Perkin-Elmer, Netherlands 
dNTPs (dATP, dCTP, dGTP, dTTP) Fermentas, St. Leon Roth 
Gene RulerTM (1 kb DNA ladder)     Fermentas, St. Leon Roth 
DNA molecular weight standard  
6 x DNA loading dye Fermentas, St. Leon Roth 
Random primers (3µg/µl)     Invitrogen, Karlsruhe 
TMB Solution (HRP substrate)    Uptima, France 
TOP 10 chemically competent E.coli   Invitrogen, Karlsruhe 
 
3.2.8 Software 
BioEdit Sequence Alignment Editor 
FinchTV Version 1.3.1, Geospiza Inc.  
Macromedia Freehand MX 
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3.3 Methods 
3.3.1 Genomic analysis 
3.3.1.1 Genotyping of founder animals and F1 generation 
In order to identify transgenic pigs, genotyping PCR was performed on tissue samples 
of piglets. For this, ear punches were obtained from three-day-old piglets and stored at 
-20°C until further processing.  
 
For genotyping of founder animals, genomic DNA was isolated in 1.5 ml reaction 
tubes from approximately 100 mg of shredded tissue using the following protocol. All 
steps were carried out at room temperature unless indicated otherwise. 
 
Composition of lysis buffer 
160 mM Sucrose 
80 mM EDTA pH 8.0 
100 mM Tris/HCl pH 8.0 
0.5% SDS  
 
Add 400 µl lysis buffer and 30 µl Proteinase K (10 mg/ml) to tissue, mix   
Incubate at 60°C overnight  
Centrifuge 5 min, 16,100 g 
Transfer supernatant to fresh tubes 
Add 400 µl sodium chloride 4.5 M, mix 
Add 300 µl phenol-chloroform-isoamylalcohol (PCiA)  
Pivot in automatic swivel unit 15 min  
Centrifuge 10 min, 16,100 g  
Transfer aqueous phase to fresh tubes 
Repeat PCiA extraction twice: add 300 µl PCiA, pivot 10 min, centrifuge 2.5 min 
Add 550 µl 2-propanol to precipitate DNA  
Transfer DNA successively into 2 tubes with 1 ml EtOH 70% each  
Incubate in EtOH 70% overnight 
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Discard EtOH 70% 
Air dry DNA pellet 10 min  
Resolve DNA in 55 µl 10 mM Tris/HCl  
Mix repeatedly for 1 hour 
 
DNA concentration was measured at 260 nm using a GeneQuant Pro 
spectrophotometer. For genotyping PCR analysis, isolated gDNA was diluted with 10 
mM Tris/HCl to a concentration of 100 ng/µl. 
Genomic DNA of F1 generation pigs was isolated using NexttecTM Genomic DNA 
Isolation Kit (Nextecc Biotechnologie GmbH, Leverkusen) according to the 
manufacturer’s protocol. 
 
In both cases genotyping PCR was performed in 0.2 ml reaction tubes in a total 
volume of 25 µl as follows: 
 
Composition of reaction mix 
2.5 µl 10x PCR-Buffer 
2.5 µl MgCl2 (25mM) 
2.5 µl dNTPs (2mM) 
0.4 µl forward + 0.4 µl reverse primer (10 µM) 
0.2 µl Taq polymerase (5 U/µl) 
1 µl DNA-template 
15.5 µl aqua bidest. 
 
Cycler protocol 
2 min 95°C  denaturation 
30 sec 95°C  denaturation 
30 sec xx°C  annealing at PCR specific temperature 
1 min 72°C  elongation 
GO TO Step 2 34x 
10 min 72°C  final elongation  
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15 min 4°C  termination of reaction 
 
Transgene specific primers were used to identify the respective transgenes. In 
addition, a house-keeping gene, the ubiquitously expressed β-actin, was amplified in 
parallel to verify integrity of isolated genomic DNA. For details of genotyping 
primers used and their respective annealing temperatures, see Table 3.1. 
 
3.3.1.2 Duplex PCR 
For discrimination of homozygous from heterozygous transgenic offspring, duplex 
PCRs were established for the GalKO and the hTM locus. One transgene specific and 
two wild-type sequence specific primers were employed in each duplex PCR. Details 
of the primers used are given in Table 3.1.  
PCRs were performed in 0.2 ml reaction tubes in a total volume of 25 µl as follows: 
 
Composition of reaction mix 
2.5 µl 10x PCR-Buffer 
2.5 µl MgCl2 (25 mM) 
2.5 µl dNTPs (2 mM) 
0.4 µl first + 0.4 µl second + 0.4 µl third primer (10 µM) 
0.2 µl Taq polymerase (5 U/µl) 
1 µl DNA-template 
15.5 µl aqua bidest. 
 
Thermocycling for duplex PCR was performed according to the cycler protocol 
detailed above for initial genotyping PCR. 
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Table 3.1: Details of genotyping primer pairs used in the identification and 
characterisation of transgenic founders and offspring. 
Transgene Primer pairs Annealing temperature Amplicon size 
CAG-LEA CAGf/LEAr 56°C 790 bp 
CD46 CD46ex2F/CD46ex3R 62°C 425 bp 
HLA-E HLAEf/HLAEr 62°C 500 bp 
hTM hTM1101f/hTM1608r 58°C 508 bp 
hTM
+/-
  hTM43f1/hTM44r1/hTM44r4                   56°C  570 bp/1200 bp 
INS-LEA LEAf/neof 61°C 993 bp 
GalKO
+/-
 neoPf/GGTAf22/GGTAr21  60°C 940 bp/570 bp  
        
Actin pACTB954f/pACTB1919r 58°C 971 bp 
+/- 
 indicates zygosity discriminating PCR 
 
3.3.1.3 Agarose Gel Electrophoresis 
After completion of PCR amplification, a 0.7% agarose gel was prepared from a 0.7% 
Universal Agarose/1x TAE buffer solution in a microwave. After cooling the mixture 
to approximately 55°C, ethidiumbromide (0.5 µg/ml) was added and the gel was left 
to set in a gel electrophoresis chamber (OWL Inc., USA). 2.5 µl of DNA loading 
buffer (10x) were added to each 25 µl PCR sample. The gel electrophoresis chamber 
was filled with 1x TAE buffer and samples and a DNA molecular weight standard 
were loaded into individual gel slots. By applying an electric current (Power Pac 300 
Gel Electrophoresis Unit; BioRad, Munich) to the gel electrophoresis chamber, DNA 
fragments were separated according to their size and could be visualised afterwards 
under UV-light. This allowed analysis of PCR products in relation to the DNA 
molecular weight standard.  
 
3.3.1.4 Southern Blot 
For determination of transgene copy numbers and numbers of integration sites, 
southern blotting was carried out on genomic DNA of founder animals, involving the 
visualisation of genomic DNA fragments containing a defined sequence.  
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DNA separation: 
For this, genomic DNA was digested by restriction enzymes in 1.5ml reaction tubes in 
a total volume of 60 µl per sample as follows: 
 
15 µg gDNA 
4 µl restriction enzyme 
Ad 60 µl aqua bidest. 
Incubate overnight at 37°C 
 
The next day, 7 µl of DNA loading buffer (10x) were added to each sample, which 
were then loaded onto a 1% Universal Agarose/TAE gel prepared as described above. 
DNA fragments were separated according to their size and analysed in relation to a 
DNA molecular weight standard. 
For details of restriction enzymes used see Table 3.2  
 
 
Table 3.2: Conditions for genomic fragmentation and probe establishment for 
Southern blotting. 
Transgene Enzyme Probe Annealing temperature Length Hybridisation 
hTM-neo EcoRI neoSENf/neoSr 56°C 707 bp 58°C 
hTM-bla HindIII PGK41f/bla343r 56°C 893 bp 56°C 
CAG-LEA XbaI neoSENf/neoSr 56°C 707 bp 58°C 
INS-LEA XbaI neoSENf/neoSr 56°C 707 bp 58°C 
 
Blotting: 
For further processing the DNA was transferred to a Hybond-N+ Nylon Membrane 
(GE Healthcare, Munich). To achieve this, the DNA in the agarose gel was first 
treated as follows: 
 
Incubate 45 min in depurination solution 
Wash 2x with aqua bidest. 
Incubate 45 min in strand break solution 
Wash 2x with aqua bidest. 
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Incubate 20 min in neutralisation solution 
Wash 2x with aqua bidest. 
Incubate 20 min in 5x SSC  
 
Subsequently, the DNA was blotted onto the membrane in a semi-dry manner. For 
this, the gel was placed upside down onto cling film (Saran Barrier Food Wrap; Dow, 
USA). Two layers of Whatman paper (Roth, Karlsruhe) and multiple layers of 
absorbent tissue were placed on top. To facilitate capillary transfer of the DNA onto 
the membrane, additional weight was applied on top and transfer was carried out over 
24 hours. 
Then DNA was crosslinked to the membrane under 0.120 J/cm2 UV light (Vilber-
Lourmat, France) and stored at room temperature. 
 
Hybridisation: 
DNA fragments containing the transgene were detected by probes specific for the 
neomycin or blasticidin resistance cassette in the transgene construct. For this, the 
probes were amplified by PCR from plasmids containing the vectors.  
PCR was carried out according to a standard protocol as described for genotyping 
PCRs above. For details of primers and annealing temperatures used in the 
establishment of probes for the different transgenes, see Table 3.2. 
 
The PCR products were separated on 1% Universal Agarose/TAE gels prepared as 
described above, eluated from the gel using QiaexII Gel Extraction Kit (Qiagen, 
Hilden), and DNA concentration of eluates was determined in relation to a DNA 
molecular weight standard on 1% Universal Agarose/TAE gels.  
 
Prior to hybridisation the membranes were placed in 80 mm glass tubes (Zefa, 
Harthausen), pre-wetted with 5x SSC and incubated in 30 ml prehybridisation buffer 
(Church Buffer) under permanent rotation at  58°C in an incubator (H. Saur, 
Reutlingen) for 1 hour. 
The probes were then radio-labelled with α32P-dCTP (Perkin-Elmer, Netherlands) 
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according to the following protocol: 
 
7 µl Klenow 10x Bu  
50-100 ng DNA probe 
10 µl Random primer (3 µg/µl) 
Ad 50 µl aqua bidest. 
 
Probe DNA was denaturated at 97°C for 10 minutes. After incubation on ice for 2 
minutes, 20 µl of hybridisation mix was added to each sample. 
 
Hybridisation mix:  
3 µl C-Mix (0.33 mM of each dATP, dGTP, dTTP) 
5 µl α 32P-dCTP (3000 Ci/mmol) 
1 µl Klenow exo- 
Ad 20 µl aqua bidest. 
 
Probe labelling was performed at 37°C for one hour. Unincorporated nucleotides were 
separated from the labelled probes by centrifugation through Sephadex G-50 columns 
(Amersham, UK). The purified and labelled probes were denaturated at 97°C for 5 
minutes and cooled on ice. Meanwhile, the prehybridisation buffer was exchanged for 
fresh Church Buffer in which the labelled probes were diluted. 
Hybridisation of the probes to the membrane was carried out overnight at 58°C under 
permanent rotation. 
The next day, the hybridisation solution was discarded and the membrane was washed 
twice with low-stringency buffer at room temperature and afterwards twice with high-
stringency buffer at 58°C. Then the membrane was placed on a coated filter paper 
(Roth, Karlsruhe), wrapped in cling film, and exposed to x-ray film (FujiFilm Corp., 
Japan) in an x-ray cassette (Rego, Augsburg) for at least one day at -80°C.  
The exposed x-ray films were developed using developing and fixing solution 
(AGFA-Gevaert, Belgium) according to the manufacturer’s instructions and 
subsequently analysed. 
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3.3.1.5 Inverse Polymerase Chain Reaction (inverse PCR) 
Inverse PCR was performed in order to clarify the unknown genomic DNA flanking 
regions of the transgene at the insertion site. Figure 3.2 gives an overview of inverse 
PCR procedure. 
All steps were carried out at room temperature unless indicated otherwise. 
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Figure 3.2: Inverse PCR overview. Genomic DNA was isolated from cells of transgenic 
animals. Isolated gDNA was then digested with restriction enzymes (here: PstI) and, following that, 
ligated to form circular DNA fragments. Primer pairs complementary to the transgene sequence were 
designed to face apart on linear DNA fragments but face towards each other once DNA has been 
circularised. Two rounds of PCR amplification using nested primer pairs were then performed on the 
circularised DNA. PCR amplicons were sequenced to clarify the previously unknown gDNA flanking 
regions of the transgene. Primer binding sites are indicated by black arrows. 
 
3.3.1.5.1 Genomic DNA isolation 
Genomic DNA was isolated in 1.5 ml reaction tubes from cultured cells of transgenic 
founders grown to confluence on a 10 cm cell culture dish analogously to the protocol 
used for gDNA isolation from tissue samples of founder animals. 
After completion of the isolation process, DNA concentration was measured at 260 
nm using a GeneQuant Pro spectrophotometer and adjusted to 500 ng/µl by diluting 
with 10 mM Tris/HCl. 
 
3.3.1.5.2 DNA fragmentation 
Restriction digest of genomic DNA was performed to generate linear DNA fragments 
with defined ends. For details of restriction enzymes used see Table 3.3. The total 
volume of 30 µl per digestion sample was composed as follows in 1.5 ml reaction 
tubes: 
 
3 µl Restriction enzyme buffer 
1 µl Restriction enzyme 
24 µl aqua bidest. 
2 µl gDNA (equals 1 µg gDNA) 
 
After mixing carefully, samples were incubated at 37°C overnight. The next day PCiA 
extraction according to the following protocol was carried out: 
 
Adjust volume to 150 µl with aqua bidest. 
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Add 100 µl PCiA 
Extract by pivoting for 1 min  
Centrifuge 2.5 min, 16,100g  
Transfer aqueous phase to new tube 
Add 15 µl 3M NaOAc 
Add 400 µl EtOH 100% 
Store at -80°C 30 – 60 min 
Centrifuge 30 min, 16,100g, 4°C 
Wash in EtOH 70% overnight 
Centrifuge 2.5 min, 16,100g  
Discard supernatant 
Air dry DNA pellet 6 min  
Resolve in 30 µl 10 mM Tris/HCl  
 
10 µl of resolved, digested gDNA was mixed with 12.5 µl aqua bidest. and 2.5 µl 
DNA loading buffer (10x) and loaded onto a 1% agarose gel to verify digestion 
success. The gel was prepared from a 1% Universal Agarose/TAE buffer solution as 
described above. 
The remaining 20 µl of digested gDNA were diluted with 100 µl 10 mM Tris/HCl and 
used for further processing. 
 
3.3.1.5.3 Circularisation of DNA fragments 
Digested and diluted gDNA was ligated overnight at room temperature in a total 
volume of 40 µl in 1.5 ml reaction tubes to circularise DNA. Each reaction mix was 
composed as follows: 
 
4 µl 10x ligation buffer 
4 µl T4 DNA ligase 
12 µl aqua bidest. 
20 µl digested gDNA  
Termination of the reaction by 15 min 65°C 
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3.3.1.5.4 Nested PCR 
For amplification of DNA sequences on circularised fragments, (nested) PCR 
amplification was performed in a total volume of 25 µl in 0.2 ml reaction tubes. For 
general principle of nested PCR see Figure 3.3. 
 
Composition of reaction mix 
5.0 µl 5x Herculase-Buffer 
2.5 µl dNTPs  
0.35 µl forward + 0.35 µl reverse Primer  
0.2 µl Herculase II 
1 µl DNA-template 
15.6 µl aqua bidest. 
 
Cycler-protocol 
2 min 95°C  denaturation 
30 sec 95°C  denaturation 
30 sec 58°C  annealing 
3 min 72°C  elongation 
GO TO Step 2 39x 
10 min 72°C  final elongation 
15 min 4°C  termination of reaction 
 
After completion of PCR amplification, samples were used as DNA templates for 
nested PCR amplification. For this, each sample was used undiluted and in a 1:100 
dilution with aqua bidest. Reaction mix and cycler protocol were the same as in the 
first amplification. Primers used were nested.  
For an overview of restriction enzymes and primer pairs used for the different 
transgenes in the inverse PCR process, see Table 3.3 
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Figure 3.3: Nested PCR. 
Sense and antisense primers are designed complementary to known sequence. Amplification of DNA 
sequence between primers is carried out by PCR. A second primer pair complementary to sequence of 
DNA amplicons is designed (= nested primers). DNA fragments are amplified a second time. PCR 
products can be further processed for cloning and sequencing. Primers are indicated by green arrows.
1
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  Table 3.3: Restriction enzymes and primers used for nested inverse PCR 
Transgene Founder Restriction enzyme Primers 5' end Primers 3' end 
      1. PCR 2.PCR 1.PCR 2.PCR 
hTM #9943 EcorI 
hTMr1 
hTMf25 
hTMr2 
hTMf24 
neokanr 
bGHpAf1 
PGKr 
neokanf 
    HindIII 
hTMr1 
hTMf22 
hTMr2 
hTMf21 
hTM2100r 
bGHpAf1 
hTM2050r 
neokanf 
    NcoI 
hTMr1 
hTMfs3f 
hTMr2 
hTMf23 
bla241r 
bGHpAf1 
bla343r 
neokanf 
    PstI nd nd 
bGHpAr3 
bGHpAf1 
bGHpAr4 
neokanf 
    XbaI 
hTMr1 
hTMf27 
hTMr2 
hTMf26 
bGHpAr3 
bGHpAf1 
bGHpAr4 
neokanf 
  #9948 BamHI 
hTMr1 
hTMf1b 
pTMSr 
hTMf2a 
bGHpAr3 
bGHpAf1 
bGHpAr4 
neokanf 
    EcorI 
hTMr1 
hTMf25 
hTMr2 
hTMf24 
bGHpAr3 
bGHpAf1 
bGHpAr4 
neokanf 
    HindIII 
hTMr1 
hTMf22 
hTMr2 
hTMf21 
hTM2100r 
bGHpAf1 
hTM2050r 
neokanf 
    NcoI 
hTMr1 
hTMfs3f 
hTMr2 
hTMf23 
bGHpAr3 
bGHpAf1 
bGHpAr4 
neokanf 
    PstI 
hTMr1 
hTMs6f 
pTMSr 
hTMf2b 
bGHpAr3 
bGHpAf1 
bGHpAr4 
neokanf 
    TaqI 
hTMr1 
hTMf1b 
pTMSr 
hTMf1a nd nd 
    XbaI 
hTMr1 
hTMf27 
hTMr2 
hTMf26 
bGHpAr3 
bGHpAf1 
bGHpAr4 
neokanf 
  #9949 BamHI 
hTMr1 
hTMf1b 
pTMSr 
hTMf2a 
bGHpAr3 
bGHpAf1 
bGHpAr4 
neokanf 
    EcorI 
hTMr1 
hTMf25 
hTMr2 
hTMf24 
bGHpAr3 
bGHpAf1 
bGHpAr4 
neokanf 
    HindIII 
hTMr1 
hTMf22 
hTMr2 
hTMf21 
hTM2100r 
bGHpAf1 
hTM2050r 
neokanf 
    NcoI 
hTMr1 
hTMfs3f 
hTMr2 
hTMf23 
bGHpAr3 
bGHpAf1 
bGHpAr4 
neokanf 
    PstI 
hTMr1 
hTMs6f 
pTMSr 
hTMf2b 
bGHpAr3 
bGHpAf1 
bGHpAr4 
neokanf 
    TaqI 
hTMr1 
hTMf1b 
pTMSr 
hTMf1a nd nd 
    XbaI 
hTMr1 
hTMf27 
hTMr2 
hTMf26 
bGHpAr3 
bGHpAf1 
bGHpAr4 
neokanf 
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3.3.1.5.5 DNA Eluation 
After preparation of a 1% UltraPureTMAgarose/TAE buffer gel analogously to the 
method described above, 2.5 µl DNA loading dye (10x) was added to each of the 
samples from the nested PCR, which were then loaded onto the gel. DNA separation 
was performed as detailed above. After visualisation, appropriate DNA strands were 
excised from the gel and extracted using a QiaexII Gel Extraction Kit (Qiagen, 
Hilden) following the manufacturer’s protocol. Then 
 
2 µl DNA eluate 
2 µl DNA loading buffer (10x) 
15 µl aqua bidest. 
 
were loaded onto a 1% Universal Agarose/TAE buffer gel prepared as described 
above. A DNA molecular weight standard allowed determination of DNA 
concentration in eluate. 
 
3.3.1.5.6 Ligation  
Eluated DNA fragments were inserted into pJet plasmid cloning vector (Fermentas, 
St. Leon Roth) in a ligation reaction as follows: 
 
2 µl 10x ligation buffer 
1 µl T4 DNA ligase 
1 µl pJet (5ng/µl)  
15-30 ng DNA eluate 
Ad 20 µl aqua bidest.  
 
Ligation was carried out overnight at room temperature. Ligase was deactivated by 15 
min 65°C. 
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3.3.1.5.7 Heat Shock Transformation 
Plasmid vectors containing the DNA inserts were transformed into E.coli TOP10 
competent cells according to the following protocol: 
  
Thaw up competent cells carefully on ice 
Add 5 µl of ligation 
Mix carefully, avoid re-pipetting 
20 min on ice  
45 sec at 42°C 
2 min on ice 
Add 1 ml LB-Medium 
45 min 37°C  
Centrifuge 5 min, 2,300g 
Resuspend pellet in 100 – 200 µl of the supernatant 
Plate on LB-Amp (50 µg/ml) agar dishes 
Cultivate overnight at 37°C 
 
The next day, individual colonies were picked from the agar dishes and inoculated 
individually into 2.5 ml LB-Amp (50 µg/ml) medium each. Cultivation was carried 
out at 37°C overnight whilst shaking. 
 
3.3.1.5.8 Plasmid preparation 
Preparation of plasmids from the overnight liquid cultures was carried out as follows: 
 
Centrifuge overnight cultures 10 min, 1,300g, discard supernatant 
Resuspend pellet in 750 µl STE and transfer to 1.5 ml tubes  
Centrifuge 5 min, 4,500g, discard supernatant 
Resuspend pellet in 200 µl Plasmid A 
Add 400 µl Plasmid B, 5 – 7 x mix (don´t vortex), 5 min on ice 
Add 300 µl Plasmid C, 5 – 7 x mix (don´t vortex), 3 min on ice 
Centrifuge 10 min, 16,100g 
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Transfer supernatant to new tube 
Add 4 µl RNase A (10 mg/ml) 
Incubate 45 min 37°C 
Add 300 µl PCiA, 1 min shake 
Centrifuge 2.5 min, 16,100g 
Transfer aqueous phase into new tube 
Add 650 µl 2-propanol, invert 
Centrifuge 10 min, 16,100g, discard supernatant 
Wash pellet in 700 µl EtOH 70% 
Centrifuge 2.5 min, 16,100g, discard supernatant 
Air dry pellet 6 min 
Resolve pellet in 55 µl 10 mM Tris/HCl 
  
DNA concentration was measured in a GeneQuant Pro spectrophotometer at 260 nm, 
and approximately 2 µg were used for qualitative analysis by restriction digestion. 
  
3.3.1.5.9 Restriction digest 
 
2 µl 10x restriction enzyme buffer 
0.2 µl restriction enzyme  
2 µg Plasmid 
Ad 20 µl aqua bidest.  
 
After overnight incubation at 37°C samples were loaded onto a 1% Universal 
Agarose/TAE buffer gel prepared as described above to determine ligation and 
transformation success. Samples displaying appropriate restriction digestion patterns 
were chosen for further processing. 
 
3.3.1.5.10 PEG precipitation 
Precipitation of DNA for sequencing was carried out as follows: 
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20 µl plasmid preparation 
20 µl PEG-MgCl2 
20 µl aqua bidest. 
 
Equilibrate 10 min  
Centrifuge 20 min 15,700g 
Wash in 100 µl EtOH 70% overnight 
Centrifuge 2.5 min, 16,100g   
Air dry 6 min 
Resolve in 20 µl 10 mM Tris/HCl 
 
DNA concentration was measured at 260 nm in a GeneQuant Pro spectrophotometer. 
Subsequently, samples were diluted with 10 mM Tris/HCl to a DNA concentration of 
30 ng/µl to serve as template for sequencing. 
 
3.3.1.5.11 Sequencing 
Sequencing of samples was performed in 0.2 ml reaction tubes in a total reaction 
volume of 10 µl. Each sample was sequenced twice, once with a pJet forward primer 
and another time with a pJet reverse primer. 
 
Composition of each reaction mix 
4 µl 5x sequencing buffer 
1 µl Big Dye 
1 µl primer (10 µM) 
2 µl template 
2 µl aqua bidest. 
 
Cycler-protocol 
1 min 95°C  denaturation 
5 sec 95°C  denaturation 
10 sec 50°C  annealing 
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4 min 60°C  elongation 
GO TO Step 2 39x   
15 min 4°  termination of reaction 
 
3.3.1.5.12 EtOH precipitation 
After sequencing amplification, DNA was precipitated from the reaction mix as 
follows: 
 
Add 2.5 µl 125 mM EDTA into PCR-lid, spin down 
Add 30 µl EtOH 100%, transfer to 1.5 ml tube 
Incubate on ice 5 min 
Centrifuge 30 min, 15,700g, 4°C 
Wash pellet in 50 µl EtOH 70% 
Centrifuge 2.5 min, 15,700 
Air dry pellet 6 min  
Resolve DNA in 30 µl aqua bidest. and transfer to sequencing plate (Abgene® PCR 
Plates; Thermo Scientific, UK) 
 
Capillary electrophoretic separation of DNA samples was carried out at the German 
Mouse Clinic, Helmholtz Centre, Neuherberg. 
 
Nucleotide sequences were bioinformatically analysed using FinchTV Version 1.3.1, 
Geospiza Inc. and BioEdit Sequence Alignment Editor. 
 
 
3.3.2 Expression analysis 
 
For transgene expression analysis tissue was either obtained in the form of ear 
punches or as an organ spectrum. 
Ear punches of approximately 0.5 cm2 were taken from three-day-old manually 
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fixated piglets. Tissue was either shock frozen in liquid nitrogen and stored at -80°C 
or transferred to 15 ml reaction tubes filled with 4% PFA. 
Pigs sampled for organ spectrum analysis were anaesthetised with Ketamine (2 ml/10 
kg) and Azaperon (0.5 ml/10 kg) i.m. Following that the animals received a vein 
catheter and were then euthanized with T61 (1 ml/10 kg) i.v. Organs were explanted 
postmortally without delay and samples of approximately 1 cm3 were either shock 
frozen in liquid nitrogen and stored at -80°C or transferred to 4% PFA. 
 
3.3.2.1 Protein isolation 
For protein isolation frozen tissue was pulverised using a mortar and pestle and 
approximately 100 mg were homogenised in a sterile 2 ml reaction tube with 750 µl 
homogenising buffer of the following composition: 
 
1.25 ml 1 M Mannitol 
0.2 ml 2 M Sucrose 
0.1 ml 0.5 M EDTA (pH 8.0) 
0.5 ml 0.1M PIPES/Tris (pH 6.7) 
Ad 10 ml aqua bidest. 
 
After 30 min centrifugation at 4,100g, 4°C, supernatant was transferred to fresh 
reaction tubes and protein concentration was measured using bovine serum albumin 
(BSA) as standard protein. For this, 500 mg BSA was dissolved in 5 ml homogenising 
buffer of the above composition and dilutions of 25 µg/ml, 20 µg/ml, 15 µg/ml, 10 
µg/ml, 5 µg/ml and 1 µg/ml were prepared. 
Standards and samples were measured in a GeneQuant Pro spectrophotometer at 595 
nm using Roti®-Quant according to the manufacturer’s instructions.   
 
3.3.2.2 Enzyme-Linked Immunosorbent Assay (ELISA) 
In order to perform qualitative and quantitative evaluation of transgenic protein, 
ELISAs were carried out in 96 well immuno plates (Maxisorp; NuncTM, Denmark). 
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Experiments were performed for CAG-LEA transgene expression analysis. 
Antibodies used were directed against the human IgG fragment of the transgene 
construct and reaction was measured against a human serum protein calibrator (Dako, 
Denmark) in dilutions of 1:11,900, 1:59,500, 1:297,500, 1:1,487,500 and 1:7,437,500. 
For reaction development chromogenic substrate for the horseradish peroxidase 
system was used. The following protocol was employed in carrying out the 
experiments: 
 
Dilute primary antibody (polyclonal rabbit anti-human IgG; Dako, Denmark) 1:570 in 
coating buffer 
Add 100 µl to each well  
Cover with self-adhesive plastic covers and incubate overnight at 4°C 
Discard well contents 
Wash 3x with 200 µl washing buffer per well 
Dilute standard and samples to appropriate concentrations in washing/dilution buffer 
Add 100 µl to each well 
Cover and incubate 2 hours at room temperature 
Discard well contents 
Wash 3x with 200 µl washing buffer per well 
Dilute secondary antibody (polyclonal rabbit anti-human IgG/HRP; Dako, Denmark) 
1:4800 in washing/dilution buffer 
Add 100 µl to each well 
Cover and incubate 1 hour at room temperature 
Discard well contents 
Wash 3x with 200 µl washing buffer per well 
Add 100 µl 3,3’,5,5’-tetramethylbenzidine (TMB) substrate  (Uptima, France) to each 
well 
Cover and incubate 7 min at room temperature 
Add 100 µl Stop solution 
 
Colour development was read immediately by measuring extinction at 490 nm and 
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620 nm reference wave length through the bottom of the microwell plate in an ELISA 
reader (Tecan, Austria). Protein concentrations in samples were calculated by 
Magellan software (Tecan, Austria) using the standard as a reference. 
 
3.3.2.3 Immunohistochemistry 
For immunohistochemistry, samples were initially preserved in 4% PFA as described 
above. 
Immunohistochemical staining and evaluation of tissue samples was carried out by Dr. 
Nadja Herbach (Department of Veterinary Pathology, Ludwig-Maximilians-
Universität, München) for CAG-LEA and INS-LEA transgenes, and Dr. Claudius 
Faber (Institute of Pathology, Ludwig-Maximilians-Universität, München) for 
GALKO, CD46 and hTM according to their specific protocols.  
Briefly, samples were taken from 4% PFA, placed in embedding cassettes and 
embedded in paraffin. A series of tissue sections was cut from paraffin blocks using a 
microtome and mounted onto glass slides. These sections were then stained 
immunohistochemically using specific antibodies. After visualisation of 
immunoreactivity and counterstaining, samples were analysed for putative transgene 
expression on protein level.  
Particulars of antibodies, chromogens and counterstains employed in the different 
stainings are given in Table 3.4 
 
Table 3.4: Immunohistochemical procedures 
Antigen Primary antibody Detection system Chromogen Counterstain 
Gal mouse anti-α-Gal-epitope, goat anti-mouse IgM,  DAB Hematoxylin 
  monoclonal, 1:5 biotinylated 1:100     
CAG-LEA rabbit anti-human IgG,  swine anti-rabbit IgG,  DAB Hemalaun 
  polyclonal, 1:50  HRP-conjugated 1:100     
CD46 mouse anti-human CD46,  Histofine Simple Stain AEC Hematoxylin 
  monoclonal, 1:10 Rat MAX PO     
hTM mouse anti-human TM,  Histofine Simple Stain AEC Hematoxylin 
  monoclonal, 1:300  Rat MAX PO     
INS-LEA rabbit anti-human IgG, swine anti-rabbit IgG, DAB Hemalaun 
  polyclonal, 1:50  HRP-conjugated 1:100     
DAB: 3,3’diaminobenzidine tetrahydrochloride; AEC = aminoethylcarbazole 
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3.3.3 Calculation of inbreeding coefficient 
For calculation of the inbreeding coefficient, an ancestral table of the individual in 
question was drawn (Figure 3.4 (A)) according to the so called point system described 
in LeRoy (1966). This system leads to a calculation of the unadjusted inbreeding 
coefficient F’x according to the following formula: 
 
F’x = ∑ (½) 
n+n’+1     n = number of generations between parental generation and 
common ancestor on the paternal side 
n’ = number of generations between parental generation 
and common ancestor on the maternal side 
 
This system yields the correct inbreeding coefficient if none of the common ancestors 
are inbred themselves. Otherwise the resulting value has to be adjusted accordingly.  
Ancestry of the founder animals investigated in this thesis and employed in 
establishing transgenic breeding herds is not known. We defined this inbreeding 
coefficient as basal level 0. 
The table drawn for calculation of the inbreeding coefficient of transgenic offspring 
was divided in an upper (OT) and a lower half (UT) for the maternal and the paternal 
ancestry. An individual is only then inbred if a common ancestor is to be found in 
both halves of the table. In order to calculate the inbreeding coefficient each ancestral 
generation (F0 –Fxx) is given a point weight (P) and the total point value of a 
common ancestor is calculated according to the following rules: 
 
- common ancestors in OT and UT are connected across the central dividing line 
- if the offspring of a specific ancestor is the same in OT and UT, the connection 
between the ancestor in OT and UT is cancelled 
- if parts of the ancestry repeat themselves in OT and UT, all connections 
between common ancestors are cancelled except the ones that are furthest to 
the left of the table 
- connecting lines within the same generation are given the point value indicated 
for that generation at the top of the table 
- connecting lines between two adjacent generations are allocated the value of 
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the generation on the right times two 
- if a connecting line skips a generation the value of the generation to the right is 
timed by four (or six if two generations are skipped) 
- all point values are added up and the inbreeding coefficient is taken by 
inserting the total calculated point value into Figure 3.4 (B) 
 
 
 
 
Figure 3.4: Example of tables for calculation of inbreeding coefficient of individual 
‘x’. (A) Ancestral table for individual ‘x’; connecting lines of common ancestors on maternal and 
paternal side have been drawn; (B) Table for reading of unadjusted inbreeding coefficient F’x  
Tables adapted from LeRoy (1966) 
 
 
3.3.4 Design of breeding schedules 
Breeding schedules were designed using Macromedia Freehand MX software while 
taking into account the calculated inbreeding coefficients of potential offspring and 
segregation patterns of transgenes according to Mendelian rules of inheritance. 
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4 RESULTS 
 
4.1 Identification of suitable breeding herds  
In order to satisfy demand for a regular supply of donor animals for 
xenotransplantation experiments, breeding herds of pigs displaying 
xenotransplantation-relevant transgene expression were to be established. Planned 
experiments included donor animals with GalKO/CD46/HLA-E expression for blood 
perfusion studies utilising the fore limbs, hearts and kidneys of these animals and 
GalKO/CD46/hTM transgenic pigs for pig-to-baboon heart transplantation and pig-to-
cynomolgus monkey kidney transplantation. Up until now donor animals for these 
studies had been derived from recloning experiments of the original founders with 
proven transgene expression. This strategy, however, had been too inefficient and 
cost-intensive to ensure regular supply of donor animals in sufficient quantities. 
Creating a feasible breeding strategy that satisfies the demand for transgenic offspring 
provided a suitable alternative. All currently performed experiments are covered by 
the DFG Transregio Research Unit “Xenotransplantation” (FOR 535) which provided 
the basis for calculation of required numbers of donor animals per year. An outline of 
the number of experiments with each of the different transgene combinations is given 
in Table 4.1. This compilation served as a ground for estimating the size of the 
breeding herds according to aspired numbers of litters per year.  
In these experiments the eventual goal was to utilise donor animals transgenic for 
GalKO/CD46 and either HLA-E or hTM. However, double instead of triple transgenic 
animals were to be used during a transition period where breeding had not produced 
the full set of transgenics yet.      
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Table 4.1: Planned number of xenotransplantation experiments 
Transgene 
Pig-to-baboon 
heart 
Pig-to-cyn. monkey 
kidney 
Perfusion 
heart  
Perfusion 
kidney  
Perfusion 
limb  
GalKO/CD46  8*         
GalKO/CD46/hTM 8 12       
hTM     3 5   
CD46/HLA-E     3    5* 
GalKO/CD46/HLA-E     3   5 
*Double transgenic animals will be used until triple transgenic variants are available. 
 
Additionally, animals expressing only one or two of the transgenes in varying 
combinations were to be used in the organ perfusion experiments in order to provide 
an opportunity for comparison of the singular and cumulative effects of the different 
transgenes.  
Taking into account that average litter sizes similar to those in wild-type breeding 
herds are to be expected in the breeding of transgenic pigs (Martin et al. 2004; Mir et 
al. 2005; Shibata et al. 2006; Williams et al. 2006) and that transgenes adhere to 
Mendelian laws of inheritance (Aigner et al. 1999), a mean litter size of 10 piglets 
with 25% desired transgene combinations was assumed. Thus four litters of 
GalKO/CD46/HLA-E and 10 litters of GalKO/CD46/hTM transgenic pigs per year 
were aimed for in order to fulfil the requirements for transgenic donors.  
Since it can be expected that one sow will generate two litters per year, a breeding 
strategy involving two GalKO/CD46 boars, two GalKO/HLA-E sows and five 
GalKO/hTM sows was designed. For ease of handling and decline of fertility with 
age, boars in the breeding herd are to be replaced every two years and sows every 
three. 
 
4.2 Selection of founder animals 
For establishment of transgenic breeding herds, suitable founder animals were chosen 
from the available material on the basis of genomic and expression analysis with 
regard to transgene status.  
GalKO/CD46 boars with well-characterised transgenic properties (Ekser et al. 2010; 
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Lin et al. 2010) that had been obtained from Revivicor Inc. were re-established at the 
MVG, Badersfeld. From these efforts, two GalKO/CD46 transgenic boars were gained 
in June (#9872) and August (#9896) 2009 which were raised until sexual maturity and 
are now being utilised in breeding. 
HLA-E transgenic pigs had been established at the MVG, Badersfeld and were 
characterised for their transgene expression as reported by Weiss et al (2009). 
Breeding of these initial founders generated three HLA-E transgenic sows in June 
2008 (#9713) and June 2009 (#9864, #9869). These three animals are now being 
employed in establishing a GalKO/CD46/HLA-E breeding herd. 
 
4.3 Expression and functional analysis of novel transgenic lines 
Additionally, potential founder pigs for new transgenic lines from litters derived from 
nuclear and embryo transfer have been characterised for their transgenic properties on 
the basis of genomic and expression analysis. The conclusions drawn from these 
analyses provided the foundation for the choice of founder animals which were to be 
re-cloned and utilised in the breeding of pigs carrying the novel transgenes. 
 
4.3.1 hTM 
hTM transgenic founder animals were derived from two different strategies. In one 
case the hTM-neo vector was used to establish single transgenic pigs. Three litters 
generated by NT and ET and born in August and December 2008 provided a total of 
eight piglets. Genotyping PCR on genomic DNA isolated from ear punches of three 
days old piglets determined seven of them as hTM transgenic (Figure 4.1 (A)). 
Immunohistochemical staining of tissue sections demonstrated strong transgene 
expression in all examined organs of animal #9781, while the litter mates #9780 and 
#9782 did not show consistent expression across all organs (Table 4.2).  
In order to receive information about the transgene copy number and the number of 
integration sites in the genome, Southern blotting on isolated genomic DNA was 
conducted. Taking into account the restriction sites within the transgene vector and the 
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feasible array of transgene copies in the genome this revealed the integration of only a 
few copies of the transgene at one single site in founder #9781, while it can be 
assumed that the examined litter mates display a more complicated transgene 
integration pattern (Figure 4.2). Boar #9781 was therefore chosen for re-cloning. 
Table 4.3 outlines the NTs and ETs performed in re-establishing boar #9781, which 
led to the birth of boar #9943 in December 2009. This animal has been utilised as a 
founder in the establishment of the GalKO/CD46/hTM breeding herd.  
At the same time, animal #9744 has undergone re-cloning attempts (Table 4.3). This 
boar had also been genotyped positive for the hTM-neo vector (Figure 4.1 (A)) and 
southern blotting indicated a single integration site of one copy of the transgene 
(Figure 4.2). Transgene expression capacity was verified by immunohistochemical 
staining of tissue sections, where this particular animal showed strong hTM 
expression in all examined organs (Table 4.2). 
Additionally, the hTM-bla vector was established on the GalKO/CD46 background 
obtained from Revivicor Inc. From this effort, four potential founder pigs were gained 
in January 2010 of which three were analysed positive for the hTM-bla transgene in a 
genotyping PCR (Figure 4.1 (B)). Immunohistochemical staining of tissue sections 
demonstrated strong hTM expression across all examined organs in animals #9947 
and #9948. Animal #9949 showed equivalent expression in ear and heart tissue, 
however, staining of other organs was markedly weaker than in the two litter mates 
(Table 4.2). Boar #9948 was therefore chosen as suitable founder animal for 
GalKO/CD46/hTM breeding. Re-cloning efforts for this animal are summarised in 
Table 4.4. Boar #1103, a clone of #9948 born in December 2010, is currently being 
raised for breeding. 
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Figure 4.1: Genotyping of genomic DNA isolated from hTM transgenic founder 
animals and littermates. (A) Genotyping PCR for hTM-neo founders; (B) Genotyping PCR for 
hTM-bla founders; A 508 bp band is amplified if the transgene has been incorporated into the genome; 
wild-type DNA produces no signal; β-actin served as a control for DNA integrity. PCR conditions were 
as shown. 
 
Figure 4.2: Southern Blot of genomic DNA derived from hTM transgenic founder 
animals. Southern blotting of hTM-neo founders and wild-type control. Whereas #9780 and #9782 
show an identical transgene integration pattern, the other animals constitute independent founders. 
 
 
M
a
rk
e
r
W
T
9
7
4
2
9
7
4
4
9
7
8
0
9
7
8
1
9
7
8
2
M
a
rk
e
r
W
T
9
7
4
2
9
7
4
4
9
7
8
0
9
7
8
1
9
7
8
2
 
Results 
 
 
 
78 
 
Table 4.2: Transgene expression levels of hTM founder animals determined by 
immunohistochemical staining of organ sections. 
Founder Transgene Ear Heart Lung Muscle Kidney Liver Spleen 
#9742 hTM 3 3 3 3 3 3 3 
#9743 hTM 0 0 0 0 0 0 0 
#9744 hTM 3 3 3 3 3 3 3 
#9780 hTM 3 2-3 1 nd 3 0 nd 
#9781 hTM 3 3 3 nd 3 3 nd 
#9782 hTM 3 2-3 1 nd 3 1 nd 
#9947 Gal 0 0 0 0 0 0 0 
  CD46 3 3 2 2 1 3 2 
  hTM 3 3 3 3 3 3 3 
#9948 Gal 0 0 0 0 0 0 0 
  CD46 3 1 1 1 1 1 1 
  hTM 3 3 3 nd 3 3 3 
#9949 Gal 0 0 0 0 0 0 0 
  CD46 3 1 1 1 1 3 1 
  hTM 3 3 1 nd 2 1 0 
Expression grading: 0 = absent; 3 = very strong 
Data provided by Dr. Julius Faber, Institute of Pathology, LMU Munich 
 
 
 
Table 4.3: Re-cloning of hTM-neo founders 
Founder NT/ET Pregnancy Delivery Offspring Weaned 
#9744 Dec. 2008 - - - - 
  Dec. 2008 - - - - 
  Jan. 2009 + + 2 0 
  Jun. 2009 - - - - 
  Jun. 2009 - - - - 
#9781 Jun. 2009 + - - - 
  Aug. 2009 + + 1 #9943 
  Aug. 2009 - - - - 
  Sep. 2009 - - - - 
  Sep. 2009 + + 1 0 
Data provided by Dr. Mayuko Kurome and Dr. Barbara Keßler 
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Table 4.4: Re-cloning of hTM-bla founder 
Founder NT/ET Pregnancy Delivery Offspring Weaned 
#9948 Mar. 2010 - - - - 
  April 2010 - - - - 
  April 2010 + + 1        0 
  May 2010 + + 6        3* 
  June 2010 + + 4        3* 
  June 2010 + + 2        1* 
  Aug. 2010 + + 4  #1103 
  Aug. 2010 + + 4        2* 
  Aug. 2010 + + 3        0 
  Sep. 2010 - - - - 
  Sep. 2010 - - - - 
  Sep. 2010 + + 4        0 
  Oct. 2010 + + 4   1*  
  Oct. 2010 + - -        - 
  Nov. 2010 + + 1 nd 
  Nov. 2010 + + 1 nd 
* Offspring was utilised as donor in xenotransplantation experiments 
Data provided by Dr. Mayuko Kurome and Dr. Barbara Keßler 
 
 
4.3.1.1 Clarification of hTM transgene integration site 
In order to aid selection of breeding material, clarification of the hTM transgene 
integrations sites in the genome was attempted with the aim of establishing zygosity 
specific duplex PCRs that allow for the discrimination of hemi- from homozygous 
transgenic animals. For this, inverse PCR was performed on genomic DNA isolated 
from hTM founder animals. 
In pig #9781 two hTM-neo transgene-transgene links could be identified. Both were 
in a head to tail orientation, however, while in one case transgene ends on both sides 
of the connection were complete, the other link suggested that one transgene copy was 
missing 9.2 kb of its head part (Figure 4.3 (A)). Additionally, DNA sequences of 915 
bp and 467 bp were generated that did, in part, not match the transgene sequence, 
making amplification into the adjacent regions of the 5’ and 3’ ends of the transgene 
likely. DNA data base searches of the porcine genome with the unknown flanking 
sequence did not provide an indication of the region concerned. However, the 915 bp 
fragment amplified from across the 5’end of the transgene sequence into the genomic 
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region contained a pig specific repetitive element, thereby confirming the genomic 
nature of the unknown sequence.  
In a subsequent step, primers were designed complementary to the identified unknown 
DNA sequences beyond the 5’ and 3’ end of the transgene. From these a DNA 
fragment was amplified by conventional PCR from wild-type alleles that overlapped 
the sequence generated by inverse PCR on each end. Using this 1075 bp wild-type 
fragment in conjunction with the flanking regions identified beyond the primer 
binding sites, a new data base search was conducted with a DNA fragment of 2278 bp 
length. In this case the porcine genome again yielded no matching sequence. 
However, searches in the closely related bovine and the well characterised human 
genome identified a region within the CCDC132 gene around exon 21 that matched 
the unknown sequence to between 76% and 78%. More detailed analysis of the region 
concerned revealed an hTM-neo transgene integration site 182 bp upstream of exon 21 
of the CCDC132 gene. Additionally, it became obvious that in transgenic alleles 790 
bp of the wild-type sequence had been replaced by the transgene (Figure 4.3 (B)). The 
absence of any other amplicons from inverse PCR that could not be correlated with 
the integration site in the CCDC132 gene in conjunction with the previously analysed 
Southern blot strongly supports the notion that this integration site is the only one in 
animal #9781. Combining the knowledge gained from inverse PCR and Southern 
blotting, the integration of three transgene copies, one of them truncated, the other two 
complete, at a single integration site is the most likely explanation. Within this site, 
two different arrays would fit the restriction pattern of both the Southern blot and the 
transgene connections found by inverse PCR (Figure 4.4 (A)(B)).  
For the hTM-bla vector integration site, genomic DNA of two animals was examined 
by inverse PCR. Integration locus clarification has not been possible in either of them 
so far. However, numerous transgene-transgene links have been found in animal 
#9948, several of them indicating a row of complete transgene copies whereas some 
appeared to be truncated at the 5´ end. Most of the transgene-transgene connections 
were found to be assembled in a head to tail orientation, but one link was of a tail to 
tail nature (Figure 4.5 (A)). #9949 displayed a presumably less complicated 
integration pattern compared to #9948. Only one head to tail transgene link could be 
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identified in which case both transgenes appeared to be complete (Figure 4.5 (B)). 
 
 
 
 
Figure 4.3: Integration site determination of hTM-neo. Either the 5´ end or the 3´ end of the 
transgene served as an anchor in inverse PCR using primers indicated as black arrows. The restriction 
sites used for fragmentation of genomic DNA are shown. The constructs are in accordance with Figure 
3.1. (A) Two different transgene-transgene links in head-to-tail orientation could be identified; the 
homologies of the flanking sequences to the transgene construct are represented by thin lines. (B) Two 
different transitions of transgene to genomic sequence were identified. Conventional PCR revealed that 
these sequences are in close proximity to each other on wild-type alleles. Homology of the unknown 
porcine sequence to the human and bovine genome suggested integration of the transgene within the 
porcine CCDC132 gene near exon 21. 
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Figure 4.4: Feasible transgene integration patterns of hTM-neo. Combining the findings in 
inverse PCR and Southern blotting where three distinct bands were identified (see Figure 4.2), three 
transgene copies have presumably been integrated in founder #9781, two complete, one truncated. The 
truncated transgene is either placed in the middle (A) or at the 3’ end of the integration site (B). The 
constructs are in accordance with Figure 3.1 with the positions of the EcoRI sites used for genomic 
fragmentation in Southern blotting indicated. The localisation of the neomycin-resistance-specific 
probe is displayed as a black bar and the lengths of the hybridised fragments are indicated. 
 
  
 
 
 
 
Results 
 
 
 
83 
 
 
Figure 4.5: hTM-bla transgene-transgene links in founder animals. Either the 5´ end or 
the 3´ end of the transgene served as an anchor in inverse PCR using the primers indicated as black 
arrows. The restriction sites used for fragmentation of genomic DNA are shown. The constructs are in 
accordance with Figure 3.1. While #9948 displays a complex integration pattern with either head-to-tail 
or tail-to-tail links (A), inverse PCR revealed only one transgene-transgene transition in #9949 in head-
to-tail orientation (B). 
 
4.3.2 INS-LEA 
Two founder litters for INS-LEA yielded nine piglets in February 2009. These 
animals were initially examined for their transgene status. For this, a genotyping PCR 
was performed on genomic DNA isolated from ear punches taken from three day old 
piglets (Figure 4.6 (A)). Seven piglets could be shown to carry the INS-LEA 
transgene in their genome. Southern blotting on genomic DNA was conducted and 
showed a different restriction pattern for each of the examined individuals. Thus they 
all constituted independent founders with unique integration sites (Figure 4.6 (B)). 
Copy numbers of integrated transgenes were estimated by analysis of the specific 
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restriction pattern and comparison of signal intensity to wild-type DNA mixed with 
stoichiometric equivalents of the transgene vector construct. From this, #9816 and 
#9818 were found to contain only one copy of the transgene, while the others 
contained more. 
Animals #9813, #9814, #9816 and #9818 survived to an age of three months and were 
then sacrificed for organ spectrum expression analysis. Figure 4.7 shows 
immunohistochemical stainings of pancreas and kidney sections of these animals. 
Because the INS-LEA construct contains a porcine insulin promoter which controls 
the transgene, expression should be confined to pancreas islets, where this particular 
promoter is active. Founders #9813 and #9814 showed strong transgene expression 
islet specifically (Figure 4.7 (A), (B)), while pancreas sections of #9816 and #9818 
stained only weakly for the transgene product (Figure 4.7 (D)). As expected, 
expression was absent from all kidney sections (Figure 4.7 (C)). In integration site 
analysis, Southern blot patterns led to the assumption that both well expressing pigs 
#9813 and #9814 contained four copies of the transgene at only one integration site, 
making them equivalent in their suitability as founders for an INS-LEA transgenic 
line. Both animals were therefore chosen to be re-cloned. Table 4.5 provides an 
overview of NTs and ETs conducted in re-cloning efforts for these two founder pigs. 
So far, boars #1044 and #1050, both re-cloned #9814, have been born in September 
2010 and will be raised to be utilised for breeding. 
In-vivo studies determined the functional effect of pancreas islet specific LEA29Y 
expression. For this, islet like clusters were isolated from pancreata of neonatal INS-
LEA transgenic piglets, cultured for several days and subsequently transplanted under 
the kidney capsule of NOD-SCID mice that suffered from a streptozotocin induced 
diabetes mellitus. After regaining normogylcaemia, hPBMCs were administered to 
these mice in order to restore their immune system in a humanised way. While mice 
transplanted with wild-type islets showed steadily increasing blood glucose levels, 
mice with LEA29Y transgenic islets stayed within normal ranges (Figure 4.8). 
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Figure 4.6: Genotyping and Southern Blotting of genomic DNA isolated from INS-
LEA transgenic founder animals and littermates. (A) Genotyping PCR: A 993 bp band is 
amplified if the transgene has been incorporated into the genome; wild-type DNA produces no signal; 
β-actin served as a control for DNA integrity; PCR was performed according to the conditions shown. 
 (B) Southern blotting of INS-LEA founders and wild-type DNA mixed with stoichiometric equivalents 
of the transgenic construct. All founders display independent transgene integration patterns and all 
except #9816 and #9818 contain more than one copy of the transgene. 
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Figure 4.7: INS-LEA expression. Immunohistochemical staining with human IgG antibody 
reveals pancreas islet specific expression of LEA29Y in founder animals; (A) & (B) Pancreas sections 
of founder animals #9813 (left) and #9814 (right); (C) Kidney sections of founder animals #9813 (left) 
and #9814 (right); (D) Pancreas sections of weakly expressing littermates #9816 (left) and #9818 
(right). Data provided by Dr. Nadja Herbach, Institute of Veterinary Pathology, LMU Munich. 
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Table 4.5: Re-cloning of INS-LEA founders 
Founder NT/ET Pregnancy Delivery Offspring Weaned 
#9813 Mar. 2010 - - - - 
  Mar. 2010 - - - - 
  Mar. 2010 - - - - 
  Apr. 2010 - - - - 
  July 2010 - - - - 
#9814 Jan. 2010 + - - - 
  Jan. 2010 - - - - 
  Mar. 2010 - - - - 
  May 2010 + + 2 0 
  May 2010 + + 3  #1050  
  May 2010 + + 4 #1044 
  Sep. 2010 - - - - 
  Sep. 2010 - - - - 
  Oct. 2010 + + 1 0 
Data provided by Dr. Mayuko Kurome and Dr. Barbara Keßler 
 
 
 
 
 
 
Figure 4.8: Pig-to-humanised mouse islet transplantation. INS-LEA transgenic islets retain 
their functionality after hPBMCs administration while wild-type controls fail to uphold 
normoglycaemia; hPBMCs = human peripheral blood mononuclear cells. Data provided by Lelia v. 
Bürck, LMU Diabetes Centre, Klinikum Innenstadt 
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4.3.3 CAG-LEA 
In September 2009 one litter of three CAG-LEA transgenic pigs was generated by NT 
and ET. Genotyping PCR demonstrated that all three had the transgene incorporated 
into their genome (Figure 4.9). Southern blot analysis indicated the integration of 
single transgene copy in founders #9808 and #9810, whereas founder #9809 contained 
presumably two transgene copies. Preliminary expression analysis was performed by 
immunohistochemical staining of ear tissue sections taken from three day old piglets. 
This revealed strong LEA29Y expression in animal #9908, whereas staining of the 
littermates showed no difference to the wild-type control (Figure 4.10). Because the 
controlling promoter on the CAG-LEA construct is ubiquitously active, transgene 
expression was to be expected in all organs. The piglets were therefore sacrificed at an 
age of three months and a whole organ sample spectrum was preserved and examined 
for LEA29Y expression. Immunohistochemistry again indicated well detectable 
transgene expression in animal #9908, but staining was absent from samples of 
littermates across all examined organs (Figure 4.11). The superior expression capacity 
of pig #9908 was further verified by measuring transgenic protein in serum samples 
and total protein extracts taken from CAG-LEA transgenic pigs and wild-type control. 
For this, an ELISA detecting the human IgG fragment of the LEA29Y protein was 
employed. Here it became obvious that pigs #9909 and #9910 did after all display 
transgene expression, albeit a weak one (Table 4.6). The difference in expression level 
ranged between three to nine times as much protein measured in samples of the 
strongest expressing animal #9908 compared to the weakest expressing animal #9909. 
An in-vitro assay utilising cell cultures grown from animal #9908 additionally 
demonstrated the functionality of CAG-LEA transgene expression by examining the 
binding capacity of LEA29Y expressed from transgenic cells to a porcine B-cell line 
(Figure 4.12). 
 
 
 
 
 
 
Results 
 
 
 
89 
 
 
 
Figure 4.9: Genotyping PCR of CAG-LEA founder animals. (A) A 790 bp fragment is 
amplified from genomic DNA of transgenic animals; wild-type controls generate no signal; β-actin 
served as a control for DNA integrity. PCR was performed according to the conditions shown. (B) 
Southern blotting of the three transgenic and a wild-type animal was performed. While #9808 and 
#9810 indicated a single transgene copy, #9809 appeared to contain two transgenes. 
 
 
 
 
Figure 4.10: LEA29Y expression in CAG-LEA transgenic founder pigs and control. 
Immunohistochemical staining of ear tissue sections with human IgG antibody reveals expression of 
LEA29Y in founder animals; (A) Wild-type control; (B) Well-expressing transgenic founder #9908; 
strong staining for human IgG can be detected around sweat glands; (C) Transgenic founder #9909; no 
specific staining for human IgG detectable. Data provided by Dr. Nadja Herbach, Institute of 
Veterinary Pathology, LMU Munich 
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     #9908        #9909 
 
Figure 4.11: LEA29Y expression in organ spectrum of CAG-LEA transgenic founder 
pigs. Immunohistochemical staining with human IgG antibody reveals different levels of LEA29Y 
expression in founder animals #9908 (left column) and #9909 (right column); (A) Heart; (B) Lung; (C) 
Pancreas; (D) Kidney. Data provided by Dr. Nadja Herbach, Institute of Veterinary Pathology, LMU 
Munich. 
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Table 4.6: Human IgG concentration in serum and total protein extracts of organs of 
CAG-LEA transgenic founder pigs.     
Sample Serum Heart  Kidney Pancreas Liver Lung Muscle Spleen Intestine 
#9908 2.15 2.83 2.99 4.22 2.14 8.05 2.20 2.47 5.05 
#9909 0.32 0.87 0.32 0.65 0.72 1.39 0.26 0.69 0.91 
#9910 1.22 1.27 0.88 0.63 0.84 1.42 0.64 1.38 1.32 
WT control 0.04 0.01 0.01 0.01 0.00 0.06 0.02 0.01 nd 
Positive control 15.45 nd nd nd nd nd nd nd nd 
Concentration in µg/ml was determined by ELISA using human IgG antibodies. Human serum from a 
healthy donor was used as positive control and protein samples from a wild-type pig as negative 
control. 
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Figure 4.12: Binding of transgene expressed from CAG-LEA construct to antigen 
presenting cells. Binding capacity of transgenic protein from cell culture supernatant to the porcine 
B-cell line L23 was compared to capacity of cell culture supernatant from porcine wild-type cells and to 
the synthetic drugs CTLA4-Ig and LEA29Y. Titration of cell culture supernatants revealed a linear 
regression of CAG-LEA binding capacity. Data provided by Dr. Reinhard Schwinzer, MHH Hannover 
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4.4 Breeding schedules 
Breeding schedules based on the initial availability of GalKO/CD46 boars obtained 
from Revivicor Inc. and HLA-E sows were designed with the aim of generating a 
GalKO/CD46/HLA-E breeding herd in a first instance. Because hTM transgenic 
animals were not available for breeding yet when breeding of transgenic herds started, 
the aim was to integrate this transgene lateron. Since the common background of all 
breeding herds is GalKO/CD46, it was decided to preserve these characteristics 
paternally and add HLA-E and hTM transgenes from the maternal side. Additionally, 
sows employed in breeding must also display a GalKO, because the effectiveness of 
this trait requires a full knock-out of the αGal gene, thereby necessitating 
homozygosity for this characteristic, whereas HLA-E, CD46 and hTM expression is 
detectable irrespective of their zygosity status. Figure 4.13 shows different breeding 
schedules aiming at the establishment of intial GalKO/CD46 and GalKO/HLA-E 
breeding animals derived from the available GalKO/CD46 boars and HLA-E sows.  
Generation of animals displaying the full set of required transgenes can only be 
achieved by breeding over two generations. The calculated probabilities for specific 
transgene combinations depending on transgene segregation and the level of 
inbreeding in the breeding herd both have to be taken into account when deciding on a 
suitable breeding method. Three different breeding approaches are feasible in 
establishing the breeding herds. Full-sibling mating of the F1 generation (Figure 4.13 
(A)) results in calculated 3.125% for each desired transgene combination and sex 
distribution in the F2 generation that represents the breeding herd. Similar 
probabilities can be achieved with half-sibling matings in F1 (Figure 4.13 (B)). 
However, inbreeding coefficients in the breeding herds would be twice as high with 
full-sibling matings (0.25) compared to half-sibling matings (0.125). In order to 
increase the proportions of transgenic animals in F2, father-daughter matings can be 
employed in the F1 generation (Figure 4.13 (C)). This would produce 6.25 % animals 
of each suitable sex and transgene composition in F2. Resulting inbreeding, however, 
would be comparable to F1 full-sibling matings.  
Because a rise in inbreeding coefficients of the breeding material has been shown to 
negatively correlate with productivity traits (Charlesworth and Charlesworth 1987; 
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Ralls et al. 1988; Lynch 1989; 1991), thereby decreasing numbers of available animals 
derived from the breeding herd, it was decided to favour breeding schedules that keep 
inbreeding levels as low as possible. Generation of initial breeding by half-sibling 
matings of F1 generations was thus given preference over the other options.  
 
 
 
 
 
 
Figure 4.13: Breeding schedules for establishment of GalKO/CD46/HLA-E breeding 
herd. (A): Full-sibling matings of F1 generation; Circles indicate sows, squares indicate boars; 
percentages given are the probability for specific sex and transgene conformation in offspring; F = 
Inbreeding coefficient; +/- = hetero- or hemizygous knock out or transgene; -/- = homozygous knock out. 
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Figure 4.13: Breeding schedules for establishment of GalKO/CD46/HLA-E breeding 
herd. (B): half-sibling matings of F1 generation; (C): father-daughter matings of F1 generation. Circles 
indicate sows, squares indicate boars; percentages given are the probability for specific sex and 
transgene conformation in offspring; F = Inbreeding coefficient; +/- = hetero- or hemizygous knock out 
or transgene; -/- = homozygous knock out. 
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Integration of the hTM transgene into the breeding herd can be achieved by two 
different strategies. In one case, hTM is derived from boars generated by transfection 
of the hTM vector construct into GalKO/CD46 cells from Revivicor Inc. In this case 
the genetic background of the resulting GalKO/CD46/hTM boars is identical to the 
GalKO/CD46 boars employed in the establishment of the initial breeding herds. 
Figure 4.14 (A) shows a breeding schedule built on this option. Inbreeding 
coefficients in breeding material derived from mating a GalKO/CD46/hTM boar to an 
F1 sow of the half-sibling breeding schedule in Figure 4.13 will result in an 
inbreeding coefficient of the offspring of 0.25. Additionally, probabilities for a 
GalKO/hTM sow that could be utilised within the breeding herd calculate to only 
3.125%.  
However, since the hTM vector construct had also been transfected into a wild-type 
cell line, a boar transgenic only for hTM was also available for furthering the breeding 
herd. In this schedule, shown in Figure 4.14 (B), the establishment of GalKO/hTM 
sows takes one generation longer than in the other case. But probabilities for the 
correct transgene combination are doubled and, even more importantly, the inbreeding 
coefficient of the resulting individuals had been calculated at only 0.062. Therefore, 
preference was given to introducing the hTM transgene into the breeding herd via the 
more time-consuming route.  
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Figure 4.14: Breeding schedules for incorporation of hTM into GalKO/CD46 
breeding herd. (A): hTM derived from boar #9948, triple transgenic founder with hTM on 
GalKO/CD46 background; (B) hTM derived from boar #9943, single transgenic hTM founder. Circles 
indicate sows, squares indicate boars; percentages given are the probability for specific sex and 
transgene conformation in offspring; F = Inbreeding coefficient; +/- = hetero- or hemizygous knock out 
or transgene; -/- = homozygous knock out. 
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In addition, simultaneous outbreeding of the breeding herd with wild-type animals is 
supposed to keep inbreeding at levels as low as feasible. As can be seen in Figure 
4.15, outbreeding of GalKO/CD46 boars over two or three generations with wild-type 
sows prior to backcrossing offspring into breeding herd will lower inbreeding levels 
within the breeding herd itself significantly to 0.062 or 0.031 for GalKO/CD46/HLA-
E combinations and 0.047 or 0.023 for GalKO/hTM, respectively if half-sibling 
matings are chosen for the establishment of breeding herds and hTM is derived from 
the single transgenic hTM boar.  
Since GalKO/CD46 had been chosen as the common background for all transgene 
combinations, outbreeding is being performed with respect to these transgenes, 
building on the original founder boars available and introducing wild-type blood on 
the maternal side of the breeding schedule. 
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Figure 4.15: Outbreeding schedule for lowering inbreeding coefficients in transgenic 
breeding herds. Effects of outcrossing GalKO/CD46 boars with wild-type sows over two or three 
generations on inbreeding coefficients within breeding herds; circles indicate sows, squares indicate 
boars; percentages given are the probability for specific sex and transgene conformation in offspring;  
F = Inbreeding coefficient; +/- = hetero- or hemizygous knock out or transgene; -/- = homozygous knock 
out. 
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4.5 Breeding & analysis of intermediate (F1) generations 
Table 4.7 provides an overview of matings conducted between the founder animals 
and their F1 generation offspring. These offspring are being employed in the 
establishment of triple transgenic breeding herds. Over the course of eight months ten 
matings took place which yielded a total number of 100 piglets.  
 
Table 4.7: Matings 
Mating Boar Sow Date Delivery Offspring Weaned 
1 #9896 WT #NT53 16.03.2010 09.07.2010 13 9 
2 #9872 #9864 16.03.2010 08.07.2010 7 7 
3 #9896 WT #475 13.04.2010 05.08.2010 12 10 
4 #9872 #9869 08.06.2010 29.09.2010 10 10 
5 #9896 #9713 08.06.2010 01.10.2010 13 12 
6 #9896 #9864 17.08.2010 09.12.2010 6 6 
7 #9943 WT #NT122 01.10.2010 28.01.2011 7 5 
8 #9943 WT #SH2 01.11.2010 24.02.2011 9 9 
9 #9896 #9869 18.11.2010 11.03.2011 11 nd 
10 #9896 #9713 18.11.2010 12.03.2011 12 nd 
 
 
All piglets were genotyped to determine their transgene status. For this, genomic DNA 
isolated from ear punches taken from three day old piglets was used as template in 
genotyping PCRs employing primer pairs specific for the respective transgenes. 
Transgenic DNA between the primer binding sites was amplified and could be made 
visible as bands of a defined size on agarose gels after PCR if the individual had the 
transgene in question incorporated into its genome. In each PCR, genomic DNA of an 
animal previously genotyped positive for the respective transgene served as a positive 
control in order to determine a successful amplification process. Furthermore, 
negative controls consisting of wild-type genomic DNA and aqua bidest. were utilised 
to demonstrate absence of unspecific amplifications or contamination of reaction 
mixtures. In addition, each DNA sample was amplified with a primer pair specific for 
the β-actin gene in order to verify DNA integrity.  A 971 bp fragment could be 
generated if the genomic DNA template was intact. 
Two matings between one of the GalKO/CD46 boars and a wild-type sow were 
conducted to facilitate outbreeding of the GalKO/CD46 transgene. These matings 
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produced a total of 25 offspring, of which 13 piglets could be shown to have inherited 
the CD46 transgene from the father. All offspring were heterozygous for the GalKO 
since the boar was homozygous for this trait (Figure 4.16 and 4.17). 
The initial matings for generating the core breeding herd for GalKO/CD46/HLA-E 
constituted six matings of GalKO/CD46 boars to HLA-E sows which yielded 59 
piglets. Of these piglets, 26 carried the CD46 and 22 the HLA-E transgene. Nine of 
the CD46 and the HLA-E transgenic piglets had inherited both transgenes. Again, as 
the boars were homozygous GalKO, all piglets were heterozygous for it (Figure 4.16, 
4.18 and 4.19). 
Immunohistochemical stainings of ear tissue sections of representatively selected 
animals demonstrated the absence of Gal epitopes in founder boar #9896 but 
heterozygous GalKO offspring displayed Gal epitope staining (Figure 4.20). 
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9896 × WT NT53    9872 × 9864    
# Gal CD46 HLA-E hTM  # Gal CD46 HLA-E hTM 
pig 1 † +/- - - -  X100 +/- - - - 
pig 2 † +/- + - -  X101 +/- + - - 
pig 3 † +/- - - -  X102 +/- + - - 
Y100 +/- + - -  X103 +/- - - - 
Y101 +/- - - -  X104 +/- - - - 
Y102 +/- + - -  X105 +/- + - - 
Y103 +/- + - -  X106 +/- - - - 
Y104 +/- - - -       
Y105 +/- + - -       
Y106 +/- + - -       
Y107 +/- - - -       
Y108 +/- + - -       
Y109 +/- + - -       
 
 
Figure 4.16: Genotyping of F1 generation for establishment of breeding herd. (A) 
Genotyping PCR amplified a 425 bp DNA fragment from CD46 transgenic pigs and a 500 bp DNA 
fragment from HLA-E transgenic pigs; wild-type animals yielded no signal; β-actin served as control 
for DNA integrity; (B) One litter from a GalKO/CD46 mating with wild-type for outbreeding provided 
13 piglets; eight were CD46 transgenic; (C) One litter of a GalKO/CD46 mating with HLA-E had seven 
piglets; three were CD46 transgenic, but none HLA-E. PCR conditions were as shown.  
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9896 × WT 475   
# Gal CD46 HLA-E hTM 
pig 1 † +/- nd nd - 
Y110 +/- + - - 
Y111 +/- - - - 
Y112 +/- + - - 
Y113 +/- + - - 
Y114 +/- - - - 
Y115 +/- - - - 
Y116 +/- + - - 
Y117 +/- + - - 
Y118 +/- - - - 
Y119 +/- - - - 
Y120 +/- - - - 
 
 
Figure 4.17: Genotyping of F1 generation for outbreeding. (A) Genotyping PCR amplified 
a 425 bp DNA fragment from CD46 transgenic animals; wild-type animals yielded no signal; β-actin 
served as a control for DNA integrity; (B) One litter from a GalKO/CD46 mating with wild-type for 
outbreeding purposes consisted of 12 piglets; five were transgenic for CD46. PCR conditions were as 
shown. 
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9872 × 9869     9896 × 9713    
# Gal CD46 HLA-E hTM  # Gal CD46 HLA-E hTM 
X107 +/- + + -  X117 +/- - - - 
X108 +/- nd nd -  X118 +/- + - - 
X109 +/- + + -  X119 +/- - + - 
X110 +/- - - -  X120 +/- + + - 
X111 +/- - - -  X121 +/- - - - 
X112 +/- + - -  X122 +/- - + - 
X113 +/- - - -  X123 +/- - + - 
X114 +/- - + -  X124 +/- - + - 
X115 +/- + + -  X125 +/- + - - 
X116 +/- + + -  X126 +/- + - - 
      X127 +/- - - - 
      X128 +/- + - - 
      X129 +/- - + - 
 
 
 
Figure 4.18: Genotyping of F1 generation for establishment of breeding herd. (A) 
Genotyping PCR amplified a 425 bp DNA fragment from CD46 transgenic animals and a 500 bp DNA 
fragment from HLA-E transgenic animals; wild-type animals yielded no signal; β-actin served as a 
control for DNA integrity; (B) Two litters from GalKO/CD46 matings with HLA-E yielded a total of 
23 piglets; ten were transgenic for CD46, 11 for HLA-E. PCR was performed according to the 
conditions shown. 
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Figure 4.19: Genotyping of F1 generation for 
establishment of breeding herd. (A) Genotyping 
PCR amplified a 425 bp DNA fragment from CD46 
transgenic animals and a 500 bp DNA fragment from 
HLA-E transgenic animals; wild-type animals yielded no signal; β-actin served as a control for DNA 
integrity; (B) Three litters from GalKO/CD46 matings with HLA-E yielded a total of 29 piglets; 13 
were CD46 transgenic, 10 HLA-E. PCR conditions were as shown. 
9896 × 9864    
# Gal CD46 HLA-E hTM 
X130 +/- - + - 
X131 +/- - + - 
X132 +/- - + - 
X133 +/- + + - 
X134 +/- + + - 
X135 +/- + + - 9896 × 9869    
# Gal CD46 HLA-E hTM 
X136 +/- + - - 
X137 +/- - + - 
X138 +/- - + - 
X139 +/- + - - 
X140 +/- - - - 
X141 +/- - - - 
X142 +/- + - - 
X143 +/- - - - 
X144 +/- + + - 
X145 +/- - + - 
X146 +/- - - - 
9896 × 9713    
# Gal CD46 HLA-E hTM 
X147 +/- - - - 
X148 +/- + + - 
X149 +/- + - - 
X150 +/- + - - 
X151 +/- - - - 
X152 +/- + - - 
X153 +/- + - - 
X154 +/- - - - 
X155 +/- + - - 
X156 +/- - - - 
X157 +/- - - - 
X158 +/- - - - 
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Figure 4.20: Inheritance of GalKO. Representative display of GalKO inheritance on 
immunohistochemically stained ear sections of founder and F1 offspring. (A) negative control; (B) 
positive control; (C) homozygous GalKO #9896; (D) heterozygous GalKO F1 generation offspring. 
Data provided by Dr. Julius Faber, Institute of Pathology, LMU Munich. 
 
 
Additionally, production of hTM single transgenic offspring was accomplished by 
mating the available hTM transgenic boar to two wild-type sows. This was done in 
order to provide hTM offspring for experimental purposes and generate a replacement 
boar for the current hTM boar. A total of 16 piglets were gained from these two 
matings, of which nine had inherited the hTM transgene from their father (Figure 
4.21). In order to determine inheritance of the integration pattern, all hTM-neo 
transgenic offspring were analysed by Southern blotting on genomic DNA (Figure 
4.22). Identical restriction patterns could be observed in founder #9781, its re-
established clone #9943, and F1 generation offspring of #9943. 
A representative selection of immunohistochemical stainings of ear tissue samples 
demonstrated inheritance of hTM expression capacity in transgenic offspring (Figure 
4.23). 
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9943 × WT SH2   
# Gal CD46 HLA-E hTM 
1192 +/+ - - + 
1193 +/+ - - + 
1194 +/+ - - - 
1195 +/+ - - - 
1196 +/+ - - - 
1197 +/+ - - - 
1198 +/+ - - + 
1199 +/+ - - - 
1200 +/+ - - - 
 
 
Figure 4.21: Genotyping of hTM single transgenic offspring. (A) Genotyping PCR 
amplified a 508 bp DNA fragment from hTM transgenic animals; wild-type pigs produced no signal; β-
actin served as a control for DNA integrity; (B) Two matings of hTM transgenic boar #9943 with wild-
type sows yielded 16 piglets; nine were hTM transgenic. PCR conditions were as shown. 
9943 × WT NT122   
# Gal CD46 HLA-E hTM 
1069 +/+ - - + 
1070 +/+ - - + 
1071 +/+ - - + 
1072 +/+ - - + 
1073 +/+ - - + 
1074 +/+ - - - 
1075 +/+ - - + 
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Figure 4.22: Inheritance of transgene integration pattern. #9943 was re-cloned from #9781 
and mated to two unrelated wild-type sows. All transgenic offspring (#1168-#1198) showed the same 
restriction pattern in Southern blotting, indicating a single transgene integration locus. 
 
 
 
 
Figure 4.23: Inheritance of hTM expression capacity. Representative example of 
immunohistochemically stained ear tissue sections of hTM transgenic offspring and wild-type 
littermates. (A) positive control; (B) negative control; (C) hTM transgenic offspring, (D) wild-type 
littermate. Data provided by Dr. Julius Faber, Institute of Pathology, LMU Munich. 
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4.6 F2 generations and hTM incorporation into breeding herd 
For breeding of the F2 generation and incorporation of the hTM transgene into the 
breeding herds, potential breeding material was chosen from F1 generation litters after 
genotyping and expression analysis by immunohistochemistry on tissue derived from 
ear punches of the animals (Figures 4.16 – 4.23). In order to generate the aspired 
GalKO/CD46/HLA-E breeding herd, half-siblings of the F1 generation with a 
heterozygous GalKO, and either transgenic for CD46 or for HLA-E, were to be mated 
to one another.  
Taking into account the only 3.125% probability of offspring with the correct sex and 
transgene composition, seven litters were calculated to be necessary for obtaining the 
required two homozygous GalKO/HLA-E transgenic sows. Additionally, these litters 
will produce homozygous GalKO/CD46 boars as replacements for the currently 
utilised GalKO/CD46 boars (#9872/#9896). Outbreeding will be accomplished by 
generating heterozygous GalKO boars that have been outbred over two generations 
and can be mated to sows from the breeding herd. For this, one mating of an outbred 
F1 generation heterozygous GalKO/CD46 sow with a wild-type boar has so far been 
scheduled. 
Incorporating the hTM transgene into the breeding herd will be achieved over two 
generations. Seven litters of F1 generation heterozygous GalKO/CD46 sows gained 
from mating with the available hTM boar (#9943), or one of his already generated 
offspring, will be necessary to produce four heterozygous GalKO/hTM sows. These 
sows can then be mated to F2 generation homozygous GalKO/CD46 boars and will 
have to produce a total of eight litters in order to generate the five homozygous 
GalKO/hTM sows essential in the breeding herd.  
Table 4.8 depicts the currently scheduled matings for establishment of the breeding 
herds.  
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Table 4.8: Mating schedule for establishment of transgenic breeding herds 
Mating Boar # Sow # Date Purpose 
1 X101 X129 April 2011 Gal/CD46/HLA-E 
2 WT Y100 April 2011 outbreeding 
3 9943 X105 April 2011 Gal/CD46/hTM 
4 9943 X128 April 2011 Gal/CD46/hTM 
5 X130 Y102 June 2011 Gal/CD46/HLA-E 
6 X131 Y103 June 2011 Gal/CD46/HLA-E 
7 X132 Y106 June 2011 Gal/CD46/HLA-E 
8 X130 Y108 June 2011 Gal/CD46/HLA-E 
9 X101 X129 October 2011 Gal/CD46/HLA-E 
10 X131 X145 October 2011 Gal/CD46/HLA-E 
11 9943 X142 October 2011 Gal/CD46/hTM 
12 9943 X149 October 2011 Gal/CD46/hTM 
13 9943 X150 October 2011 Gal/CD46/hTM 
14 9943 X152 October 2011 Gal/CD46/hTM 
15 9943 X153 October 2011 Gal/CD46/hTM 
 
 
4.7 Identification of transgene zygosity 
In order to define the zygosity status of transgenic offspring with respect to the 
transgenes carried, duplex PCRs were established for the GalKO and hTM. This 
allowed discrimination of hetero- or hemizygous GalKO and hTM transgenic animals 
from their homozygous or wild-type littermates.  
 
4.7.1 GalKO duplex PCR 
As is demonstrated in Figure 4.24 (A), a duplex PCR on an exemplary selection of 
homozygous GalKO animals, their heterozygous offspring and unrelated wild-type 
animals illustrates homozygosity for GalKO in pigs #1061, #1066, #9948, #9949, 
#1103 and #1104, heterozygosity in pigs #X108, #X110, #X126, #X127 and #X128 
and wild-type in pigs #1197, #1198, #1199 and #9943. In each case, a 940 bp DNA 
fragment was amplified from the GalKO allele and a 570 bp band from the wild-type 
counterpart. Homozygous animals for either GalKO or wild-type would therefore 
generate only one band of the defined size while heterozygous animals would generate 
both fragment sizes. Primer locations on the transgenic and wild-type sequences are 
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depicted in Figure 4.24 (B). It can be observed that the primers located on the wild-
type allele should theoretically also generate a DNA fragment on the GalKO locus, 
covering the whole length of the transgene. This, however, is not the case because the 
given PCR conditions do not allow the amplification of a DNA fragment that large. 
Consequently, only the DNA fragment between primers neoPf and GGTAr21 will be 
amplified from the GalKO allele. 
 
 
Figure 4.24: Zygosity of GalKO alleles. (A) A duplex PCR was established to discriminate a 
570 bp fragment amplified from the Gal-wild-type allele from a 940 bp fragment generated from the 
GalKO allele. #1197, #1198, #1199 and #9943 are transgenic animals without GalKO. #X108, #X110, 
#X126, #X127 and #X128 are offspring of a homozygous GalKO boar with WT sows regarding the Gal 
locus. #1061, #1066, #9948, #9949, #1103 and #1104 are animals re-cloned from homozygous GalKO 
pigs. The faint WT band in animal #1061 is presumably due to DNA contamination. Additionally, band 
intensity appears to provide semi-quantitative information about the zygosity of wild-type and knock-
out alleles. (B) The localisation of the primers is shown for the wild-type as well as for the knock-out 
allele. In the knock-out allele the primers GGTAf22/GGTAr21 should theoretically generate an 
additional 2.3 kb fragment but this is not amplified under the given PCR conditions detailed in (A).  
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4.7.2 hTM duplex PCR 
Analogously, a duplex PCR for the hTM-neo locus was established. Here, the 
information gained from the integration locus clarification by inverse PCR was 
utilised in order to design primer pairs that amplify a 570 bp DNA fragment from the 
wild-type allele and a 1200 bp fragment from the transgenic allele within one PCR 
reaction. Figure 4.25 shows a duplex PCR on an exemplary selection of hTM-neo 
heterozygous offspring of founder boar #9943 and their wild-type littermates. 
Heterozygosity is demonstrated for animals #1192, #1198, 1171, #1172 and #1173 
while animals #1195, #1197, #1199, #1200 and #1174 are homozygous wild-type. 
Genomic DNA of founder #9943 was used as positive control for heterozygosity, and 
genomic wild-type DNA as control for amplification of the wild-type sequence. No 
control for a homozygous hTM-neo locus could be applied because no such animal 
was available at the given time point. 
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Figure 4.25: Zygosity of hTM-neo transgene. (A) A duplex PCR was established to 
discriminate a 570 bp fragment amplified from the wild-type allele from a 1200 bp fragment generated 
from the hTM-neo transgenic allele and thus identify wild-type as well as hemi- and homozygous 
transgenic animals. #1192, #1198, #1171, #1172, #1173 and #9943 are hemizygous transgenic animals. 
#1195, #1197, #1199, #1200 and #1174 are wild-type.  (B) The localisation of the primers is shown for 
the wild-type as well as for the knock-out allele. 
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5 DISCUSSION 
 
The notion that pigs are among the most suitable species for biomedical translational 
research and as potential donors in the context of xenotransplantation has been 
prevalent for some time and has been discussed extensively by numerous authors 
(reviewed in Aigner et al. 2010). This is owed to the fact that the organ systems of 
pigs share many anatomical and physiological characteristics with humans (Smith et 
al. 1990; Rogers et al. 2008; Spurlock and Gabler 2008). Additionally, their size 
corresponds to human dimensions more closely than that of rodents does, which also 
makes sampling and handling a less materially limited and demanding task (Roberts et 
al. 2009). In their guidelines, national and international regulating authorities such as 
the European Medicines Agency require the use of a non-rodent mammal as 
experimental animal in clinical development trials (www.ema.europa.eu). Genetically 
modified pigs therefore occupy an ever increasing place in biomedical translational 
research and xenotransplantation. However, in order to draw meaningful conclusions 
from experiments, sizeable numbers of animals are required. Lead times in the 
preparation or specific time frames in the conduction of experiments demand 
predictable groups of experimental animals of specific size and at specific time points. 
This has proven to be a problematic issue in providing transgenic pigs for 
experimental purposes. 
Novel transgenic lines have been and are being established by a variety of 
technologies based on additive gene transfer with unpredictable transgene integration 
sites or site directed knock-out or knock-in methods. Somatic cell nuclear transfer 
followed by embryo transfer into oestrus synchronised recipient sows has become the 
leading technique in generating transgenic pigs (Melo et al. 2007). This method 
features beyond 90% transgenesis rates and pooling of transgenic cells derived from 
independent integration events leads to  more than 90% independent founders, as long 
term experience at the MVG has shown (unpublished data). However, it has become 
apparent that the process is also very inefficient in terms of total animals numbers 
produced. Rates of less than 5% live offspring compared to the total number of 
transferred embryos have been reported across the literature (Polejaeva et al. 2000; 
Oback 2008; Palmieri et al. 2008) which makes the cloning procedure appropriate for 
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establishing novel transgenic pigs but raises the question if this technique is suitable 
for reproducing already established lines by nuclear and embryo transfer. 
As Tables 4.3, 4.4 and 4.5 demonstrate, re-cloning of pigs after expression analysis of 
founder litters and selection of the most suitable founders at the MVG, Badersfeld has 
proven to be a tedious issue. For example, six attempts at re-cloning hTM-neo founder 
pig #9781 delivered only one single animal which, fortunately, survived the neonatal 
period and could be raised until sexual maturity (Table 4.3). Re-cloning INS-LEA 
founders #9813 and #9814 has been equally difficult. 14 nuclear and embryo transfers 
resulted in only four pregnancies that actually delivered. From these, only two animals 
(#1044, #1050) were weaned (Table 4.5). Re-cloning of hTM-bla founder boar #9848 
appears to have generated slightly more live offspring. However, taking into account 
that 16 nuclear and embryo transfers dates  produced only 11 weaned piglets that 
could be utilised in experiments or raised for breeding, this calculates to an average of 
0.7 piglets derived from one nuclear and embryo transfer . Or, if only nuclear and 
embryo transfers from which a pregnancy was established are taken into account, this 
number still averages at less than one piglet per NT/ET (Table 4.4). Therefore, this 
method had been discarded as a means for routinely re-producing transgenic pigs for 
experimental purposes, as outcome is too unpredictable and, consequently, too time, 
space and human and material resource intensive.  
Breeding transgenic pigs on a demand-based level rectifies these limitations. As has 
been reported before, transgenic animals generated by cloning and their offspring 
behave similarly in terms of reproductive capacity as their wild-type counterparts 
(Martin et al. 2004; Mir et al. 2005; Shibata et al. 2006; Williams et al. 2006). 
Additionally, transgenes integrated into the genome appear to be passed on to the next 
generation according to Mendelian rules of inheritance (Aigner et al. 1999). Breeding 
of transgenic pigs that has been conducted during the preparation of this thesis has 
confirmed both of these notions. Litter sizes of transgenic pigs mated to either another 
transgenic or to wild-type individuals averaged 10 piglets per litter which is similar to 
what has been reported for wild-type litters (McGlone and Pond 2003) and also 
reflects the wild-type breeding experience gained at the MVG.  
Transgene inheritance appeared to adhere to Mendelian rules. As has been shown in 
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Figures 4.16, 4.18 and 4.19, eight matings of GalKO/CD46 boars to either wild-type 
or HLA-E transgenic sows generated a total of 84 piglets. Calculated numbers of 
offspring transgenic for CD46 and/or HLA-E should have constituted 27.25 CD46, 
14.75 HLA-E and 14.75 CD46/HLA-E transgenic piglets. Effectively, gained 
transgenic offspring represented 29, 11 and 10, respectively. Even though total 
numbers for HLA-E and CD46/HLA-E transgenic offspring are slightly less than 
expected, individual single litters have brought more transgenic offspring than 
calculated, while others have produced less. Matings involving the hTM-neo boar 
#9943 have produced nine transgenic piglets when, mathematically, only eight should 
have been generated (Figure 4.21).  
Since transgenes are passed on to the next generation adhering to Mendelian rules of 
inheritance, they also segregate accordingly. This lowers probabilities of specific 
transgene combinations in multiple transgenic animals as long as each transgene is 
incorporated as a single vector construct into the genome. However, it also effects 
segregation of multiple integration sites of a single transgene. This can become a 
problem in offspring generations, as transgene expression capacity of the individuals 
cannot be foreseen. Detailed expression analysis would therefore have to be conducted 
on each pig, which is in many cases not practicable as animals would have to be 
sacrificed for this and could therefore not be utilised in breeding or experiments. 
Consequently, segregation of transgenes has to be avoided. This is only possible if 
animals are selected for breeding that only possess one single transgene integration 
site in the first instance. Segregation of multiple copies of the transgene at one 
integration site would only be possible if these transgenes were relocated to multiple 
integration sites by recombination first, which would then be able to segregate. This, 
however, is a theoretical possibility but extremely unlikely. As Aigner et al. (1999) 
have demonstrated, transgene integration sites apparently remain stable in over 20 
generations of breeding without reassortment of individual copies. Southern blotting 
of the hTM-neo founder and his offspring demonstrated that indeed all transgenic 
piglets derived from this boar displayed the same restriction pattern as their father 
(Figure 4.22), suggesting cross-generational stability in integration conformation of 
the transgenes. Selection of founder animals displaying a single integration site, even 
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with more than one transgene copy, is therefore a viable means of preventing 
segregation.  
If avoidance of transgene segregation is accomplished, expression patterns of founder 
animals can be assumed to be passed on to offspring (Bordignon et al. 2003; Brunetti 
et al. 2008). Even though epigenetic silencing of promoters or coding sequences has 
been observed in lentiviral transgenesis (Kearns et al. 2000, Hofmann et al. 2006), this 
effect seems to occur mainly with viral sequences. F1 generation offspring of 
GalKO/CD46 and hTM-neo boars could therefore have been expected to display 
transgene expression on a level comparable to their fathers’. Indeed, analysis of 
immunohistochemically stained ear sections (Figure 4.23) of F1 hTM-neo offspring 
reinforced the notion that expression patterns of transgenes are inherited to the next 
generation. Thus, expression analysis of founder animals with a single transgene 
integration site presumably constitutes a sufficient method of ensuring reliable 
expression levels also in later generations. 
Furthermore, with the knowledge of transgene vector construction, namely the 
promoter part of it, expression of the transgene can be anticipated in cell types or 
tissues in which the controlling promoter is active. Therefore, it might appear to be an 
option to confine expression analysis of potential founder animals to tissues that can 
be harvested without sacrificing the animals in question. For example, CAG-LEA 
founders were expressing the immunomodulatory LEA29Y transgene ubiquitously. 
Initial expression analysis on ear tissue sections (Figure 4.10) and in blood serum 
samples (Figure 4.6) gave a good indication of the expression capacity of each of the 
three founders and could be gained without killing the animals. This can be seen as an 
important finding, as the extremely low efficiency in re-cloning primary cells from 
animals killed for expression analysis hinders generation of breeding stock. However, 
specific projects often require the site-specific expression of a particular transgene. 
Potential founder animals for INS-LEA transgenic pigs, for example, had to be 
sacrificed for analysis because expression of the transgene was expected to be limited 
to pancreatic ß-cells which could not feasibly be obtained from living pigs. Moreover, 
during the analysis of hTM-bla founders it became apparent that even though initial 
expression analysis in the form of immunohistochemically stained ear sections (Figure 
 
Discussion 
 
 
 
117 
 
4.2) would lead to the assumption that all three potential founders were equal in their 
transgene expression capacity, further examination proved this conjecture wrong. In 
depth expression analysis on the basis of immunohistochemical staining of organ 
spectra brought to light that expression was indeed on a comparable level in some, but 
not in all investigated tissues. For example, animal #9849 expressed hTM well in 
heart tissue on a level similar to that of the two litter mates but staining of lung, liver 
or kidney tissue was markedly weaker. The same phenomenon could be observed in 
the selection of hTM-neo founders. Ear tissue sections of litter mates #9780, #9781 
and #9782 all stained equally well in immunohistochemical evaluation. However, 
staining of a range of organs showed the differing expression capacity of the litter in, 
for example, lung and liver tissue. In both cases, the animal that expressed best in all 
examined organs was chosen as founder boar, for hTM-bla pig #9848 and for hTM-
neo pig #9781. This choice, however, would not have been possible, had expression 
analysis been confined to a more superficial level. 
In-depth expression analysis thus appears to be a prerequisite in the selection of 
founder animals that are to be utilised in breeding transgenic pig lines. Choosing 
suitable founders with respect to their transgene expression capacity and limiting the 
likelihood of transgene segregation in future generations by only employing animals 
with a single integration site in breeding ensures viable transgene inheritance. This is 
the case for single transgenic animals; however, if multiple transgenic vectors have 
been incorporated into the genome, segregation of these transgenes becomes 
inevitable. As a result, probabilities for specific transgene combinations in offspring 
can decrease to very low numbers, necessitating many litters in order to generate a 
certain number of particular pigs.  
The low probability of multi-transgene inheritance might be overcome by choosing 
only animals for breeding that carry the transgenes on both alleles. In this case, all 
offspring would be hemizygous for each transgene. This, however, requires 
knowledge of transgene zygosity, which in turn can only be determined if integration 
sites are known. Additionally, even though employing homozygous transgenic 
animals in breeding or mating animals with identical transgenic properties to each 
other increases the numbers of transgenic offspring it also heightens inbreeding levels. 
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This is due to the fact that only a very limited amount of breeding stock is available in 
the case of transgenic pigs and founder animals are usually confined to only one 
genetic background for each transgene. Consequently, homozygosity for a trait can 
only be achieved by mating related animals and pigs with identical transgenic 
properties will necessarily have been derived from the same founder. But rising 
inbreeding coefficients lower productivity of breeding stock and the viability of 
offspring (Charlesworth and Charlesworth 1987; Ralls et al. 1988; Lynch 1989; 1991). 
This collides with requirements for large numbers of offspring if probabilities for 
transgene combinations are low.  
Inbreeding should therefore be kept as low as possible within a breeding herd. Thus 
matings between animals that are related to each other should be avoided as far as 
possible and unrelated wild-type blood should be introduced from the outside on a 
regular basis. However, both of these measures again lower probabilities for specific 
transgene combinations and make them even impossible, as is the case with traits that 
have to be present in homozygosity in order to take effect, such as the GalKO. Hence 
it can be concluded that transgene inheritance and inbreeding are two conflicting 
issues that cannot be accounted for fully both at the same time. Rather a common 
ground has to be identified on which either of these issues presents the least possible 
problem. 
In order to examine the differing effect a distinct emphasis on either increasing 
transgene combination probabilities or on keeping inbreeding levels low can have on 
breeding outcome, breeding schedules for establishment of GalKO/CD46/HLA-E and 
GalKO/CD46/hTM herds were designed that account for both issues to a different 
extent (Figure 4.13). Because GalKO/CD46 was only available in the form of founder 
boars generated by re-cloning from cells of one single founder established at 
Revivicor, Inc. these transgenes had to be derived from these two boars. On the other 
hand, HLA-E was only available as sows derived from breeding the original founders 
established in 2006. And, finally, hTM had been established as a new transgene on 
two different backgrounds, once by transfecting the hTM-bla vector onto the 
Revivicor GalKO/CD46 background and once as hTM-neo on a wild-type cell line, 
both again resulting in male animals. As the GalKO needs to be bred to homozygosity 
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for an applicable effect, mating of related animals in F1 generation was inevitable 
because the GalKO could only be derived from the paternal side. Since the other 
transgenes are already functioning in a hemizygous conformation, they could be 
obtained from either the paternal or the maternal side. Figure 4.13 (A) and (B) 
demonstrate that the choice between half-sibling and full-sibling matings in F1 was 
inconsequential for the proportion of suitable transgene combinations in F2. However, 
it did have a substantial effect on the development of the inbreeding coefficient in F2 
offspring. While half-sibling matings resulted in an inbreeding coefficient of 0.125, it 
doubled to 0.25 for full-sibling matings. This can be seen as a considerable difference 
if it is kept in mind that several authors have reported average inbreeding coefficients 
in commercial pig breeds of below 0.1 (Welsh et al. 2010) and that every ten percent 
rise in inbreeding of the sow has been correlated with a 0.2 piglet reduction in litter 
size (Dickerson et al. 1954). Father-daughter matings, on the other hand, would have 
been able to double probabilities for specific transgene combinations in offspring 
(Figure 4.13 (C)). But they, too, would have resulted in inbreeding coefficients of 0.25 
in offspring. The decision was thus made to employ half-sibling matings to generate 
homozygous GalKO offspring with CD46, HLA-E or both transgenes.  
An even greater effect could be observed in deciding on where to derive the hTM 
transgene for integration into the breeding herd from. Utilising the GalKO/CD46/hTM 
founder boar, suitable animals for breeding would already have been generated within 
one generation. However, the genetic background of this founder is identical to the 
GalKO/CD46 founders, as all of them are clones of the initial Revivicor cell 
population. Thus, mating of F1 generation sows from half-sibling matings to the 
GalKO/CD46/hTM founder boar would have constituted father-daughter matings, 
resulting in 0.25 inbreeding (Figure 4.14 (A)). On the other hand, employing the 
single transgenic hTM founder and mating him to the exactly the same sows will not 
generate breeding animals in the following generation as it will be impossible to 
establish a homozygous GalKO. But offspring one generation later will not only 
display the required transgenes with twice as high a probability than in (A) but will 
also feature an inbreeding coefficient of only 0.062 (Figure 4.14 (B)). This constitutes 
a value comparable to two generations GalKO/CD46 outbreeding with wild--type 
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sows as depicted in Figure 4.15 which can thus be achieved simultaneously with 
integrating the hTM transgene into the breeding herd. 
Zygosity of transgenes becomes an important issue if transgenes are only effective in 
a homozygous conformation or if, on the contrary, homozygosity of a trait implicates 
severe disadvantages for the affected individual. For calculation of expectable 
proportions of transgenic piglets in offspring, zygosity of the parents is also the 
determining factor. In rodents, it is feasible to determine zygosity by out crossing the 
individuals in question. This, however, does not appear to be an option in pigs. 
Pregnancy lengths of approximately 115 days in pigs would make this a time-
consuming undertaking. Depending on overall body weight, European regulations 
dictate minimum floor areas for sows of up to 2.5 m2 per sow (Directive 2010/63/EU) 
for experimental animals, thus implying substantial space requirements. Furthermore, 
it is doubtful if animal welfare concurs with producing numerous litters of piglets 
solely for determining transgene zygosity of the parents. A reliable method for 
genomic analysis of the zygosity status of individuals with respect to transgenes must 
therefore be identified. 
In the establishment of the transgenic breeding herds that are being covered by this 
thesis, zygosity was not relevant for the F1 offspring generation. Zygosity of founder 
animals was known in each case and since no identical transgenes on the maternal and 
the paternal side were present, offspring was necessarily hemi- or heterozygous for the 
respective transgene. However, in F2 generation offspring the question of GalKO 
zygosity will arise and later on the other transgenes will also become relevant. 
Zygosity specific duplex PCRs that are able to amplify two different DNA fragments 
from transgenic and wild-type alleles in one PCR reaction and thus discriminate 
between homo- and heterozygous transgenic individuals were therefore to be 
established.  
In the case of the GalKO the location of the relevant DNA sequence within the 
genome was already clear, as site directed knock out of a specific gene had been 
performed. Thus, primers could be designed that cover the region in question and 
from which DNA fragments of two different sizes were amplified from the transgenic 
and the wild-type allele. As has been shown in Figure 4.23, this method is able to 
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reliably discriminate between hetero- and homozygous GalKO pigs and generates a 
570 bp DNA fragment from the wild-type locus and a 940 bp fragment from the 
knock out sequence. Because the reverse primer was placed downstream of the known 
integration site of the gene disruption vector, it could be utilised for both alleles. Two 
forward primers were placed either upstream of the Gal gene or on the knock out 
vector sequence. Consequently, DNA fragments from the wild-type allele were 
amplified from the reverse and the forward primer that had been placed upstream of 
the gene, and DNA fragments from the knock out allele were generated from the 
reverse and the second forward primer on the vector sequence. The forward primer 
upstream of the Gal gene was also able to bind on the knock out allele; however, since 
the vector sequence was larger than 4 kb, the distance between this primer and the 
reverse primer downstream of the integration site would have been too long for Taq 
polymerase to cover under the used PCR conditions. Thus, no amplicons were 
generated from this primer pair. 
In order to establish a zygosity specific duplex PCR for the hTM transgene the 
integration loci in the founder boars had to be identified first so the comparable wild-
type sequence would be known. Thus, inverse PCR was chosen as a means of 
determining integration sites of transgenes in the founders employed in breeding. 
From a technological point of view, this method is rather simple and straightforward 
(Ochman et al. 1988; 1990). Genomic DNA is fragmented, fragments are circularised 
and DNA is amplified from primers binding to the transgene sequence. Flanking 
regions of the transgene copy thereby become visible. Using this technique, it has 
been possible to successfully identify the hTM-neo integration site in founder #9781 
(Figure 4.3) and several transgene-transgene transitions in hTM-bla founders #9948 
and #9949 (Figure 4.5), including a number of truncated transgene copies. 
Additionally, inverse PCR amplified porcine genomic regions including the porcine 
thrombomodulin and the Gal gene. This can be ascribed to the porcine 
thrombomodulin promoter and the bGH-polyadenylation site of the resistance 
cassettes present in the transgene vectors on which the primer binding sites could be 
found. 
Identification of the genomic flanking region of transgenes by inverse PCR is based 
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on the assumption of complete individual transgene copies. Only then are primer 
binding sites, which need to be placed close to the 5’ or the 3’ end of the transgene, 
reliably available. Furthermore, increasing numbers of transgene copies at one 
integration site lower the probability of ascertaining the inverse PCR amplicons that 
contain parts of the genomic flanking region. Thus, failure to identify the hTM-bla 
integration locus in founder pigs #9948 and #9949 might be due to (i) the possibility 
that only truncated transgene copies are present on either transition site to genomic 
DNA or (ii) the fact that such a large number of transgene copies has been inserted at 
one site that probabilities of identifying the genomic flanking regions are extremely 
low anyway, or (iii) the circularised genomic DNA fragments are too large to be 
amplified by the PCR reaction. Several restriction enzymes for genomic fragmentation 
and a number of different primer pairs were used in each case but only a minority 
delivered amplicons after inverse PCR, which suggests that circularised DNA 
fragments might indeed have been too large in many cases for successful 
amplification. On the other hand, up to eight different restriction enzymes were tested 
in each approach with all of them resulting in calculatory mean fragment sizes of 
below 3 kb. Therefore it seems unlikely that so many of the fragments should have 
been too large for amplification. In the case of founder animal #9949, only one single 
transgene-transgene link could be identified (Figure 4.5 (B)) at all, indicating that 
failure to identify genomic flanking regions might have been due to severely truncated 
transgene copies on either transition site to the genomic sequence. In founder #9948, a 
combination of truncated transgene copies and the sheer number of copies in the 
integration site appear to be a probable explanation that the hTM-bla integration locus 
could not be clarified. The same can be said for examination of the CD46 integration 
locus in Gal/CD46 founder boars, of which results have not been included in this 
thesis. Here, too, a number of transgene-transgene transitions could be revealed but no 
genomic flanking regions. 
In order to rectify problems with too many inserted transgene copies, it might be a 
possibility to choose restriction enzymes that result in comparably large fragments 
within the transgenic sequence but possess a relatively high restriction frequency 
within genomic DNA. Thus fragments resulting from transgene-transgene links might 
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become too large for amplification by inverse PCR while fragments from genomic 
DNA might be of a suitable size. The majority of amplicons generated would 
therefore possibly contain genomic flanking regions. However, this approach would 
not account for the presence of truncated transgene copies, limiting the prospects of 
success for inverse PCR in clarification of transgene integration sites. Alternative 
measures could perhaps be found in the generation of BAC libraries for the founder 
animals in question, where probes that recognise parts of the transgenic sequence 
would be used to seperate the BACs that contain the transgene from a pool of large 
genomic DNA fragments. Sequencing of these particular BACs would then reveal the 
surrounding genomic region. Several authors have reported on the construction of 
porcine BAC libraries (Liu et al. 2010; Suzuki et al. 2000) however, high throughput 
methods for sequencing would have to be employed in order to process the masses of 
data this approach would deliver. A third option for clarifying the integration site of a 
transgene might be deep sequencing methods which enable the sequencing of whole 
genomes or at least large portions of it without requiring extraordinary amounts of 
time or money. These methods, however, are still under development and require in 
depth knowledge of the genome analysed. Since the presently available sequence of 
the porcine genome still contains large gaps, these methods are currently not feasible 
but might find their application in the future.      
In conclusion, the first systematic approach to establishing breeding herds for 
production of donor animals with multiple functional transgenes for 
xenotransplantation has been described. The selected breeding schedules represent a 
compromise between the conflicting parameters of rising inbreeding coefficients and 
efficiency of transgene inheritance. Additionally, novel transgenic pig lines have been 
identified that are to be integrated into the breeding herds and duplex PCR screening 
methods have been established to facilitate future breeding by discrimination of 
transgene zygosity. 
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6 SUMMARY 
(Re)producing transgenic pigs for xenotransplantation – selection of founder 
animals and establishment of breeding herds 
 
Xenotransplantation is discussed as an alternative treatment for end-stage organ 
failure. The pig has been widely accepted as a feasible donor species. However, it has 
to be genetically modified in order to overcome incompatibilities of the human and 
the porcine immune systems. Although profound experience in long-term breeding of 
multi-transgenic animals exists for mouse models in biomedical research, the situation 
in breeding multi-transgenic pigs is far more complicated. In contrast to small animal 
models, several limitations have to be taken into account for the pig: (i) inbreeding has 
a detrimental effect on fertility and litter size in pigs while congenic mouse strains are 
being bred with small limitations; (ii) generation times of approximately 12 months 
and pregnancies of 115 days in pigs necessitate careful breeding management; (iii) 
costs and space requirements in pig maintenance far exeed those for mice. In addition, 
insight into xenograft rejection mechanisms is still limited and further transgenes or 
novel transgene combinations might be required in the future. Thus, effective breeding 
schedules have to be designed that accomodate these limitations and allow for 
adaptation to changing transgene requirements.  
This thesis describes the design and establishment of multi-transgenic 
GalKO/CD46/HLA-E and GalKO/CD46/hTM donor herds and the characterisation of 
novel hTM and LEA29Y transgenic lines for future incorporation into the breeding 
herd. In a first step, two fertile GalKO/CD46 boars and three fertile HLA-E sows were 
selected as founders for an initial GalKO/CD46/HLA-E breeding herd into which 
further xeno-relevant transgenes were to be incorporated later on. Breeding schedules 
that accommodate the conflicting issues of inbreeding, transgene segregation and time 
requirements to different extents were designed and the most feasible strategy was 
identified. Furthermore, options for incorporation of already fertile hTM transgenic 
founder pigs into the core breeding herd were analysed.  
Chosen GalKO/CD46 and HLA-E founder animals were mated to each other and half-
sibling matings of the F1 generation offspring were selected as a method for 
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establishment of a homozygous GalKO with CD46 or HLA-E in F2 generation 
offspring. GalKO/CD46 boars were also mated to wild-type sows to facilitate 
outbreeding and thus restrict inbreeding levels within the herd. Additionally, the 
selected method for integration of the hTM transgene into the breeding herd 
necessitated matings of the hTM founder boar to wild-type sows. All F1 generation 
offspring was analysed on a genomic level to determine inheritance of transgene 
integration patterns. Additionally, inheritance of expression capacity was examined 
immunohistochemically. This facilitated selection of breeding animals for generation 
of F2 offspring.  
In parallel, analyses of potential founder animals for the novel transgenic pig lines 
hTM, INS-LEA and CAG-LEA were performed to select the most suitable individuals 
for incorporating these transgenes into the breeding herd. In each case, animals were 
chosen where Southern blotting indicated the presence of only one single transgene 
integration site to avoid segregation of integration loci in offspring. Expression of the  
transgene was examined by immunohistochemistry and ELISA in a broad range of 
organs to determine the individuals that exhibited the best expression capacity. By 
combining results of genomic with expression analysis, founders for the novel lines  
were chosen which were subsequently re-cloned to be raised for breeding. While the 
generation of a fertile founder had already been accomplished for the hTM transgene, 
INS-LEA founders have not reached sexual maturity yet.  
Comprehensive genomic analysis included the determination of transgene integration 
loci in hTM founder animals. For this, inverse PCR was chosen as a method for 
determining unknown genomic flanking regions of transgenes. The transgene 
integration site could be identified in the hTM founder that is being employed in 
breeding. Additionally, two further potential hTM founders were analysed and 
complex transgene integration patterns were clarified. However, the integration locus 
itself could not be found in these two cases.  
The information gained from hTM integration locus determination in the founder boar 
employed in breeding was utilised for establishing a duplex PCR that discriminates 
between an hTM transgenic allele and its wild-type counterpart in one single PCR 
reaction. This was done in order to facilitate discrimination of hemizygous from 
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homozygous transgenic pigs, which will be necessary from F2 generation onwards. A 
zygosity specific duplex PCR was also established for the genomically assigned 
GalKO, discriminating the wild-type from the hetero- or homozygous knockout.  
In conclusion, this thesis decribes the systematic reproduction of multi-transgenic 
donor pigs for xenotransplantation experiments. While breeding for the well-
characterised transgenes has already commenced, the established schedule also allows 
for integration of the additionally analysed transgenes once fertile founder animals 
become available. 
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7 ZUSAMMENFASSUNG 
 
Transgene Spenderschweine für die Xenotransplantation – Auswahl von 
Foundertieren und Etablierung von Zuchtherden 
 
Xenotransplantation gilt angesichts des notorischen Mangels an Spenderorganen als 
mögliche Behandlungsmethode für Organversagen im Endstadium. Das Schwein wird 
als best-mögliches Spendertier gesehen, allerdings geht man davon aus, dass mehrere 
genetische Modifikationen vorgenommen und kombiniert werden müssen, um die 
zahlreichen Inkompatibilitäten zwischen humanem und porzinem Immun- und 
Gerinnungssystem zu überwinden. Solche multi-transgenen Tiere durch somatischen 
Kerntransfer herzustellen bedeutet einen immensen Aufwand. Zucht von multi-
transgenen Tieren wird seit langem für Mausmodelle durchgeführt, aber die 
Übertragung dieser Erfahrungswerte auf Schweine unterliegt mehreren 
Beschränkungen : (i) während kongene Mausstämme mit wenigen Einschränkungen 
gezüchtet werden können, beeinträchtigt schon eine vergleichsweise geringe 
Erhöhung des Inzuchtkoeffizienten im Schwein Fertilität und Wurfgrößen; (ii) eine 
Generationszeit von 12 Monaten und Trächtigkeitsdauern von 115 Tagen erfordern 
eine genaue Zuchtplanung; (iii) Kosten und Raumbedarf in der Schweinehaltung 
übersteigen die der Mäusehaltung bei weitem. Zusätzlich zu diesen zucht-spezifischen 
Einschränkungen kommt, dass die Abstossungsmechanismen in der 
Xenotransplantation bisher nur rudimentär verstanden sind. Man kann davon 
ausgehen, dass in Zukunft weitere Transgene und/oder neue Transgenkombinationen 
erprobt werden müssen. Zuchtplanungen müssen deshalb diese Limitationen 
berücksichtigen und ausserdem an neue Anforderungen angepasst werden können. 
Diese Dissertation behandelt Planung und Etablierung von multi-transgenen 
Schweineherden mit den Transgenkombinationen GalKO/CD46/HLA-E und 
GalKO/CD46/hTM sowie die Charakterisierung neuer hTM- und LEA29Y-transgener 
Linien für die zukünftige Implementierung in die Zuchtherden. Aufgebaut wurden die 
Bemühungen auf fünf zuchtfähigen Tieren, zwei GalKO/CD46 Ebern und drei HLA-E 
Sauen. Mögliche Zuchtpläne wurden auf die gegensätzlichen Aspekte von Inzucht, 
Transgensegregation und Zeitaufwand hin untersucht und Anpaarungen nach der 
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günstigsten Variante durchgeführt. Verschiedene Varianten des Einzüchtens von hTM 
in die Zuchtherden wurden ebenfalls erwogen.  
Die Strategie basierte auf einer männlichen GalKO/CD46 und einer weiblichen 
GalKO/HLA-E Linie. Für deren Erstellung wurden GalKO/CD46 und HLA-E 
Foundertiere verpaart und Halbgeschwisterverpaarungen aus den resultierende 
Würfen geplant. Um den Zuwachs an Inzucht zu reduzieren, wurden Auszuchten von 
GalKO/CD46 Ebern mit Wildtypsauen durchgeführt. Alle F1 Tiere wurden 
genotypisiert und das Expressionsverhalten wurde immunohistologisch analysiert, um 
die Auswahl der Zuchttiere für F2 zu treffen. 
Parallel zur Erstellung der ersten Zuchtherde wurden neue Foundertiere mit den 
Transgenen hTM, INS-LEA und CAG-LEA untersucht, um die besten Tiere für die 
Einbringung dieser Transgene in die Zuchtherden auszuwählen. Dafür wurde die 
Transgenintegration durch Southern Blotting analysiert und das Expressionsverhalten 
in einer Reihe von Organen immunhistologisch und mit ELISA bestimmt. Nach der 
Auswahl der Founderlinien wurden Tiere für die Zucht durch Reklonierung erzeugt. 
Während für hTM ein zeugungsfähiger Eber schon vorhanden ist, stehen zwei INS-
LEA Eber kurz vor der Fertilität. 
Für die Aufklärung von Transgen-Integrationsorten wurden inverse PCR 
durchgeführt. Für den hTM Eber, der in die Zuchtherden integriert werden soll, 
konnten die Anzahl der integrierten Kopien und die flankierenden genomischen 
Sequenzen bestimmt werden. Für zwei weitere hTM Founder konnten ebenfalls 
Transgen-Transgen Verknüpfungen bestimmt werden, allerdings bleibt der 
Integrationsort unklar.  
Mit der F2 Generation können sowohl hemi- als auch homozygote Varianten von 
additiven Transgenen auftreten. Um diese unterscheiden zu können, wurde für die 
hTM-Linie mit dem bekannten Integrationsort eine Duplex-PCR etabliert, die das 
Wildtyp- vom transgenen Allel unterscheidet. Analog dazu wurde für den GalKO 
ebenfalls eine Duplex-PCR entwickelt, die in der Zucht auftretende Wildtyptiere von 
hetero- und homozygoten Knockouttieren unterscheidet.   
Diese Doktorarbeit beschreibt die systematische Erzeugung von multi-transgenen 
Spenderschweinen für die Xenotransplantation. Bereits beschriebene Transgene wurde 
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nach einem Zuchtplan verpaart, der auch die Einbringung neuer Transgene erlaubt.  
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